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Cancer is a disease characterized by the abnormal proliferation of cells in the 
body.  For many forms of cancer, there remain only limited and often ineffective 
treatment options available.  Treatment of cancer is problematic for several reasons that 
include the difficulty in establishing molecular targets, finding interventions that cause 
selective toxicity to cancer cells, and the uniform capability of cancer cells to evade 
apoptosis.  To address this, new strategies must be employed that take advantage of 
novel mechanisms of action to develop better therapies.  The goal of this research is to 
aid in this effort through the study of emerging targets and antitumor agents.  In these 
studies, we characterize the structure of an important target in the field of anticancer 
drug design, the quadruplex formed in the human c-MYC promoter region.  The 
oncogene c-MYC is dysregulated or overexpressed in approximately 70% of human 
cancers and contributes to many survival pathways used by cancer cells to evade 
apoptosis.  Stabilization of the c-MYC promoter quadruplex has been shown to reduce 
c-MYC expression and cause apoptosis in tumor cells.  We also examine the 
mechanisms of action of two novel classes of antitumor agents, the anthracenyl 
isoxazole amides (AIMs) and a group of 5,8-quinolinedione analogs.  We demonstrate 
interactions of the AIMs with quadruplex-forming sequences found in human telomeres, 
the c-MYC promoter, and mitochondrial DNA.  Additionally, we provide evidence that 
the AIMs can inhibit the electron transport chain of mitochondria, specifically Complex II.  
Further, we show that treatment with the AIMs causes damage to mitochondrial DNA 
and loss of the mitochondrial membrane potential, leading to the intrinsic pathway of 
apoptosis in human glioblastoma cells.  We also show a novel set of 5,8-quinolinedione 
analogs have potent antitumor activity in human breast cancer cells not related to their 
suitability as substrates for the NQO1-reductase that is often overexpressed in cancer.  
Together, this work has provided new insights to the field of anticancer drug discovery 
through characterization of an important target, the c-MYC promoter quadruplex, and 
through analysis of two novel classes of antitumor compounds, the AIMs and the 5,8-
quinolinediones. 
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Human Cancers 
Overview 
Cancer is a disease defined by the abnormal proliferation of cells in the body 
which form tumors leading to adverse health outcomes and often death.  Tumors are 
formed by cells containing genetic mutations and that have lost the normal mechanisms 
controlling cell growth, proliferation, and apoptosis.  Additionally, tumors can undergo a 
process known as metastasis and invade and damage healthy tissues throughout the 
body.  The National Cancer Institute estimates that approximately 1.7 million people will 
be diagnosed with cancer in the United States in 2018 alone (Siegel, Miller, and Jemal 
2018).  Significant progress has been made in the treatment options available to fight 
this deadly disease; the relative survival rate for cancer increased during the period of 
2004 – 2010 to 68% from only 49% from 1975 – 1977 (Mitra et al. 2015).  However, it 
remains the second leading cause of death in the United States, accounting for 
approximately 1 of every 4 deaths, and this highlights the need for development of 
improved anticancer therapies (Mitra et al. 2015; Siegel, Miller, and Jemal 2018). 
 
Brain Cancer & Glioblastoma 
It is estimated that brain and central nervous system tumors will cause 
approximately 17,000 deaths in 2018 and they are the leading form of childhood 
neoplasm, accounting for 26% of all pediatric cancers (Ostrom et al. 2014; Siegel, 
Miller, and Jemal 2018).  Additionally, metastases in the brain can stem from many 
primary tumor types including lung, breast, melanoma and gastrointestinal tumors, 
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resulting in approximately 170,000 cases per year (Ulrich H. Weidle, Niewöhner, and 
Tiefenthaler 2015). 
Glioblastoma is the most common form of brain cancer, accounting for 
approximately 15% of cases, and has an extremely poor prognosis with a median 
survival of only 12 – 15 months following initial diagnosis (American Cancer Society 
2014).  Glioblastoma tumors arise from astrocyte cells and represent the highest, Stage 
IV, classification of astrocytoma’s on the WHO scale (Young et al. 2015).  In contrast to 
more treatable forms of cancer, glioblastoma has very limited treatment options 
available.  Complete surgical resection of glioblastoma tumors is often unsuccessful due 
to the difficulty in distinguishing diseased from healthy brain tissue.  The extent of 
resection has been demonstrated to be linked to the rate of patient survival and survival 
is improved significantly when ≥ 98% of the tumor is excised; however, a greater extent 
of resection is also shown to increase the number of patients with permanent neural 
deficits due to damage to healthy neural tissue (Young et al. 2015).  In addition, 
chemotherapeutic intervention is difficult for glioblastoma and other brain tumors due to 
the blood-brain barrier (BBB) which prevents many potential small-molecule treatments 
from reaching tumors in the brain (Ulrich H. Weidle, Niewöhner, and Tiefenthaler 2015).  
Regardless of these challenges, the current most common treatment of glioblastoma is 
a combination of resection of the tumor followed by a regiment of radiation and/or 
treatment with highly cytotoxic agents such as the first-line therapy temozolomide 
(Furnari et al. 2007; Young et al. 2015).  Temozolomide is a non-specific alkylating 
agent that acts on guanine and adenine residues.  It exerts its toxicity through 
methylation of the O6 atoms of guanine causing formation of O6-methyl-guanine bases 
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in DNA.  These genetic lesions can be repaired by methylguanine-DNA-
methyltransferase (MGMT), however it is a suicide repair enzyme and as a result the 
repair capacity is limited (J. Zhang, FG Stevens, and D Bradshaw 2012).  Other primary 
treatments include the DNA alkylation agent carmustine and the DNA cross-linker 
cisplatin, both of which also exert their cytotoxic effect through damage to DNA 
(Reithmeier et al. 2010; Roux et al. 2017; Wang et al. 2017; Coluccia et al. 2018).  In 
theory and in practice this non-specific DNA damage is more toxic to rapidly dividing 
tumor cells than to senescent healthy cells.  However, the reality is that these 
treatments often lead to excess damage in healthy tissues. 
 
Evasion of Apoptosis in Cancer 
Evasion of apoptosis is an essential characteristic of cancer.  This can be caused 
through upregulation of anti-apoptotic signaling or downregulation of pro-apoptotic 
proteins.  The extrinsic pathway of apoptosis is often stunted through reduction in 
expression of death receptors on the cell surface.  Prevention of caspase-8 activation 
through upregulation and direct binding of proteins such as cFLIP to the death receptor 
complex can also prevent activation of the extrinsic pathway (Fulda 2010).  Similarly, 
the intrinsic apoptosis pathway can be inhibited through increases in expression of 
functional antiapoptotic (Bcl-2, Bcl-xL, Mcl-1) or decreases in expression of proapoptotic 
proteins (Bax, Bak, Bid, Apaf-1) (Figure 1.1) (Fulda 2009). 
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Figure 1.1 Evasion of Apoptosis in Cancer  
(Fulda 2009) 
Overexpression of antiapoptotic proteins such as inhibitor of apoptosis (IAP) proteins, 
Bcl-2, or genetic silencing/mutation of proapoptotic proteins such as Apaf-1 and Bax 
can contribute to evasion of apoptosis by cancer. 
 
Apoptosis Overview 
The two major apoptotic pathways are the intrinsic (mitochondrial-mediated) and 
extrinsic (death receptor-mediated) routes.  Both of these pathways lead to eventual cell 
death through activation of a family of serine proteases known as caspases.  Activation 
of a caspase cascade leads to proteolytic cleavage of target proteins in the cell causing 
cell death (Fulda 2010). 
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Extrinsic Apoptosis 
Death receptor-mediated apoptosis, also known as the extrinsic pathway, is 
caused by activation of death receptors on the surface of the cell.  Activation of death 
receptors leads to activation of initiator caspase-8 which can then act to cleave 
downstream effector caspase-3.  Caspase-8 also is capable of cleaving the 
mitochondrial protein Bid to tBid, causing permeabilization of the outer mitochondrial 
membrane and subsequent cytochrome c release from the mitochondria (Fulda 2010).  
 
Intrinsic Apoptosis 
Mitochondrial mediated apoptosis is characterized by activation of caspase-9 
following release of cytochrome c from the mitochondria.  Release of caspase-9 also 
causes activation of caspase-3 through formation of a large protein complex termed the 
apoptosome (Fulda 2010).  The apoptosome is formed by Apaf-1 and caspase-9 and 
requires the presence of cytochrome c and dATP.  Procaspase-9 is recruited to CARD 
motifs on Apaf-1 and this activates caspase-9 (Yuan and Akey 2013). 
 
Summary 
The goal of anticancer therapeutics is to develop treatments which selectively 
target and induce apoptosis in tumor cells.  Unfortunately, current therapies are often 
non-specific, especially in the case of brain tumors, and cause damage to healthy 
tissues.  To address this issue, it is necessary to examine novel targets in the effort to 
develop more selective and effective medicines.   
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In this work, multiple potential targets for antitumor agents are explored, and the 
significant findings are reported.  This work examines targeting quadruplex DNA 
structures, specifically the c-MYC quadruplex, for antitumor drug development.  The 
mechanism underlying a class of novel antitumor compounds, the anthracenyl isoxazole 
amides (AIMs), is also addressed in detail as it pertains to quadruplex DNA and 
interactions in the mitochondrial electron transport chain.  The work also contributes to 
studies of a novel set of synthetic analogs designed to utilize the NQO1-reductase to 
target tumor cells. 
Targets for Development of Antitumor Compounds 
Quadruplex DNA 
History 
Guanine-rich regions of DNA and RNA can form a secondary structure known as 
a quadruplex.  The study of quadruplex structures can be traced back to a report in 
1910 of solutions of guanylic acid forming gels at high concentrations, indicating the 
presence of a higher-order structure (Bang, I. 1910).  Later, this higher order structure 
was identified as helical through X-ray fiber diffraction studies and the basic unit of the 
quadruplex, now known as a G-quartet, was theorized (Figure 1.2) (Gellert, Lipsett, and 
Davies 1962). 
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Figure 1.2 G-Quartet 
Four guanines form the basic unit of the quadruplex structure, known as a G-quartet, 
through Hoogsteen bonding stabilized by surrounding a monovalent cation. 
 
Although there were some structural studies completed, quadruplex structures 
were largely ignored for a long period of time following their discovery as it was 
unknown if they had any biological significance.  However, it was later shown that these 
structures could form in guanine-rich DNA under physiological conditions and these 
guanine-rich regions were present in gene promoter and in human telomeres (Sen and 
Gilbert 1988; Sundquist and Klug 1989; Burge et al. 2006).  Following this realization, 
quadruplex structures have become the subject of significant scientific study, with the 
number of quadruplex-related articles being published increasing almost every year 
since (Figure 1.3). 
N
N
N N
N
O
R
H
HH
N
N
N
N N
O
R
H
H
H
N
N
NN
N
O
R
H
H H
N
N
N
NN
O
R
H
H
H
K
+
 9 
 
Figure 1.3 Quadruplex Publications 
Articles published per year when searching “quadruplex” on PubMed. 
 
Quadruplex Topology 
As mentioned previously, quadruplex structures can form from DNA, RNA or a 
combination of both.  The basic unit of the quadruplex is the G-quartet (Figure 1.2), 
which is comprised of four guanine nucleotides surrounding a monovalent cation such 
as sodium or potassium, held together through Hoogsteen bonding.  The monovalent 
cation compensates for the electronegative charge of the O6 oxygen atoms of the 
guanine bases and is essential for this stable conformation (Burge et al. 2006; 
Bhattacharyya, Mirihana Arachchilage, and Basu 2016).  Potassium is generally 
preferred to sodium and is observed in a square antiprismatic coordination with the O6 
atoms between the interface of two G-quartets.  Sodium is also commonly observed, 
however its smaller radius allows coordination by the O6 atoms of a single G-quartet in 
a square-planar conformation.  Other, less physiologically relevant monovalent cations 
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can also be similarly involved in the quadruplex structure, however the small atomic 
radius of lithium does not allow it to stably occupy this space (Bhattacharyya, Mirihana 
Arachchilage, and Basu 2016). 
 Quadruplexes can form as intramolecular or intermolecular arrangements, arising 
from single or multiple nucleic acid strands, respectively.  Unimolecular quadruplex 
structures arising from a single strand have been the subject of the majority of studies 
due to their physiological relevance, however bimolecular and tetramolecular 
quadruplex structures have also been characterized in solution and in crystal structures.  
The sequence motif that forms quadruplex structures is similar for both intramolecular 
and intermolecular quadruplexes with the general form of G3-5L<7G3-5L<7G3-5L<7G3-5.  The 
loop nucleotides are necessary for allowing the G-quartets to stack in a stable 
conformation, with smaller loop regions generally indicating a more stable quadruplex 
structure.  Three types of loops have been shown to form (Burge et al. 2006; 
Balasubramanian, Hurley, and Neidle 2011).  
Propeller, or strand-reversal loops, occur when the G-quartet at one side of the 
overall quadruplex is connected through a loop to the G-quartet on the opposing side.  
Diagonal loops refer to those which connect two corners of G-quartets on opposite 
sides relative to each other.  Lateral loops are those which connect two corners of G-
quartets on adjacent sides.  The types of loops formed in the quadruplex determine the 
overall topology of the quadruplex, divided into three types (Figure 1.4) (Neidle 2017). 
 11 
 
Figure 1.4 Quadruplex Topologies 
(Neidle, 2017) 
Three classes of quadruplex topology.  Antiparallel, parallel and hybrid refer to the 
strand direction on each edge of the overall quadruplex (5’ – 3’).   
 
 Parallel quadruplexes are those in which the direction of the nucleic acid strands 
on each edge of the structure run parallel to one another in the 5’ – 3’ direction.  Anti-
parallel refers to quadruplexes in which the two edges oppose the direction of the other 
two edges.  The third type is the hybrid, or mixed 3+1, type in which three of the nucleic 
acid strands on the edges proceed in the same direction and one in the opposite 
direction (Balasubramanian, Hurley, and Neidle 2011).  All of these types have been 
demonstrated experimentally, and multiple forms have even been observed for the 
same sequence in an equilibrium such as is exemplified by the sequence found in 
human telomeres (Parkinson, Lee, and Neidle 2002; Luu et al. 2006; Phan, Kuryavyi, 
Luu, et al. 2007). 
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Quadruplexes in Telomeres 
The terminal 3’-end of human telomeres have been shown to be single-stranded 
and comprised of a repeating sequence of the form TTAGGG (Burge et al. 2006).  This 
allows for formation of repeating quadruplex structures and this has been described as 
“beads on a string” (Yu et al. 2012).  However, the protein hPOT1 competes with 
quadruplex formation and allows telomerase to bind and maintain telomere length in 
cells as they divide.  Excessive disruption of hPOT1 binding by inducing quadruplex 
formation causes a DNA damage response in cells and causes them to undergo 
apoptosis (Neidle 2010).  This strategy is being actively explored as a possible 
mechanism to target for development of small-molecule anticancer therapies. 
Expression of telomerase is upregulated in over 80% of cancers, allowing tumor 
cells to rapidly divide while maintaining telomere length and preventing the degradation 
of coding DNA.  Telomerase activity is dependent on binding of hTERT, the catalytic 
subunit, to the single-stranded telomeric overhangs and hybridization of a telomeric 
RNA template to allow lengthening of the telomere.  Formation of quadruplex structures 
in the telomeric overhangs prevents the catalytic activity of telomerase.  It has been 
shown that small-molecules which bind telomeric quadruplex structures can shift the 
equilibrium to favor quadruplex formation and thereby prevent the lengthening of 
telomeres by telomerase. This results in induction of rapid senescence in tumor cells 
and activation of the DNA damage response leading to apoptosis (Figure 1.5) (Neidle 
2010). 
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Figure 1.5 Telomeric Quadruplex Induced Apoptosis 
(Neidle, 2010) 
Mechanisms of inducing apoptosis in cancer cells using the telomeric quadruplex ligand 
BRACO-19 as an example. hPOT1 and hTERT are displaced by formation of a 
quadruplex in the telomeric overhang and stabilization with the BRACO-19 ligand. 
 
Quadruplexes in Gene Promoters 
Quadruplex-forming sequences are prevalent in gene promoter regions, and 
specifically in multiple genes important to the pathogenesis of cancer.  These include 
the promoter regions of c-MYC, c-KIT, Bcl-2, VEGF, KRAS, and HIF-1α (Yang and 
Hurley 2006; Phan, Kuryavyi, Burge, et al. 2007; Dexheimer, Sun, and Hurley 2006, -2; 
Sun et al. 2005; Lavrado et al. 2015; De Armond et al. 2005).  The most well-studied is 
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c-MYC due to its overexpression in approximately 70% of all human cancers and 
multiple roles essential to tumor cell survival.  It has been demonstrated that quadruplex 
formation in the NHEIII1 region of the c-MYC promoter prevents transcription of c-MYC, 
leading to apoptosis in multiple tumor cell types (Figure 1.6) (Ou et al. 2007).  A more 
complete description of the c-MYC promoter quadruplex and its functions in cancer will 
follow in Chapter 2 (Stump et al. 2018). 
 
Figure 1.6 Reduction of c-MYC expression using a quadruplex stabilizing ligand 
(Balasubramanian, Hurley, and Neidle 2011) 
Stabilization of the c-MYC promoter quadruplex with a ligand such as TMPyP4 
interferes with binding of transcription factors and RNA polymerase II to prevent 
transcription and expression of c-MYC. 
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Another well-studied example is the quadruplexes formed in the c-KIT promoter 
region.  The c-KIT promoter contains two quadruplex-forming sequences and encodes 
for a tyrosine kinase important in the development of gastrointestinal tumors and other 
human cancers (Fernando et al. 2006; Rankin et al. 2005; Phan, Kuryavyi, Burge, et al. 
2007).  Multiple studies have demonstrated reduction in c-KIT expression in tumor cells 
following treatment with quadruplex targeted ligands (Bejugam et al. 2007; McLuckie et 
al. 2011; Balasubramanian, Hurley, and Neidle 2011).  Two quadruplex structures also 
form in the KRAS gene promoter.  KRAS is a member of the RAS family of G-proteins 
which are involved in pathways affecting cell growth and apoptosis (Morgan et al. 2016).  
Overactivation of KRAS is commonly found in cancers and leads to enhanced cell 
proliferation and loss of tumor suppressor function.  Previous studies have 
demonstrated that KRAS expression in cancer cells can be reduced using small-
molecule quadruplex binding ligands (Lavrado et al. 2015; Morgan et al. 2016). 
 
RNA Quadruplexes 
Quadruplexes have also been shown to form in RNA and are generally more 
stable than their DNA counterparts (Agarwala, Pandey, and Maiti 2015; Bugaut and 
Balasubramanian 2012; Fay, Lyons, and Ivanov 2017).  This is due to the fact that RNA 
is mostly single-stranded and the presence of a 2’-OH in the ribose sugar allowing for 
increased intramolecular interactions.  Known biological RNA quadruplexes are also 
restricted to the parallel topology.  For these reasons, the melting temperatures of RNA 
quadruplexes often exceed temperatures found in most biological systems.  
Interestingly, regardless of this remarkable stability, it has been suggested that RNA 
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quadruplexes do not form to any significant extent in vivo, and this is likely due to 
unwinding of these structures in the cell.  There is evidence of several proteins that bind 
RNA quadruplexes, and even some that can unwind these structures in vitro, such as 
DHX36 (G4 resolvase) and DHX9 (RNA helicase A) (Fay, Lyons, and Ivanov 2017).  
Several biological roles of RNA and DNA:RNA hybrid quadruplexes have been 
suggested including in transcriptional regulation, 3’-end RNA processing, pre-mRNA 
splicing regulation and mRNA translation, however the field is still developing and many 
of the details remain to be discovered (Fay, Lyons, and Ivanov 2017). 
 
Quadruplexes in Mitochondrial DNA 
It has been demonstrated that quadruplexes are also able to form in 
mitochondrial DNA (mtDNA).  Studies suggest that there are approximately 200 putative 
quadruplex-forming sequences present in the mitochondrial genome (Bharti et al. 2014; 
D. W. Dong et al. 2014).  A recent study using fluorescent compounds has suggested 
that quadruplexes in mtDNA may be suitable targets for development of anticancer 
therapies (Huang et al., 2015).  The researchers demonstrate that a set of carbazole 
ligands derivatized with pyridinium iodide, connected through varying lengths of alkyl 
chains, can bind quadruplex structures found in mtDNA.  The researchers suggest the 
mechanism of action of these compounds is through prevention of mtDNA gene 
expression leading to apoptosis (Huang et al., 2015).  This hypothesis is strengthened 
by previous studies demonstrating genes in mtDNA containing putative quadruplex-
forming sequences are more susceptible to DNA damage (Bharti et al. 2014). 
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Another area of significant interest in the involvement of quadruplex structures in 
transcription and replication of mtDNA.  A domain of mitochondrial DNA (mtDNA) known 
as conserved sequence block II (CSB II) has been demonstrated to form a parallel 
DNA:RNA hybrid quadruplex with nascent RNA during mtDNA transcription (Wanrooij et 
al. 2010; Zheng et al. 2013).  Transcription of mtDNA can be prematurely terminated 
through formation of a structure known as the D-loop, which is responsible for 
generation of the RNA primers required for initiation of mtDNA replication.  Multiple 
reports in the literature suggest the formation of the hybrid quadruplex as the 
mechanism responsible for the transition from transcription to synthesis of mtDNA 
(Wanrooij et al. 2010; Zheng et al. 2014). 
 
Methods for Study of Quadruplexes 
There are many common methods employed for the study of quadruplex 
structures.  The major methods utilized and referenced in this work are outlined below, 
however this is by no means an exhaustive list.  
 
Macromolecular X-ray Crystallography 
One of the best methods used to reveal nuances in the overall topology of 
quadruplex structures is X-ray crystallography.  Briefly, crystal growth conditions are 
evaluated using a high-throughput screening method, often in a 96-well format.  Once 
preliminary crystals are attained, the conditions can be refined further to improve the 
quality and size of the crystals.  Crystals suitable for structure determination are then 
placed in front of a detector and a focused beam of x-rays is directed at the crystal as it 
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is rotated in front of the detector.  The detector collects the diffraction pattern from x-
rays scattered as a result of the electrons present in the crystalline lattice.  From this 
diffraction pattern, a map of the electron density of the macromolecule of interest can be 
calculated and the position of the atoms can be determined with high precision (N. H. 
Campbell and Parkinson 2007; N. Campbell, Collie, and Neidle 2012; Parkinson, Lee, 
and Neidle 2002; Wei et al. 2012; Stump et al. 2018). 
 At the time of writing, over 130 quadruplex structures have been determined 
using macromolecular crystallographic methods and deposited in the RCSB Protein 
Databank, a repository for macromolecular structures.  Many of these structures also 
contain ligands bound to the quadruplex structures and this has allowed for further 
design and refinement of small molecules ligands. 
 
NMR Spectroscopy 
NMR spectroscopy is another common method employed for studying 
quadruplex structures and their interactions with ligands.  The imino protons of the 
guanine bases in both DNA and RNA quadruplexes display characteristic peaks 
between 10 – 12 ppm  in their 1H spectra (Adrian, Heddi, and Phan 2012; Bao et al. 
2017).  This allows measurement of anisotropy changes resulting from perturbation of 
the quadruplex structure with ligands.  Selectively N15 or F19 labeled nucleotide bases 
coupled with two-dimensional water-suppression NOSEY methods can also be 
employed in conjunction with molecular dynamics to accurately approximate the 
topology of specific quadruplex structures formed by different sequences of DNA and 
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RNA (Yang and Hurley 2006; Dai et al. 2011; Adrian, Heddi, and Phan 2012; Bao et al. 
2017). 
 
Circular Dichroism Spectroscopy 
Circular dichroism spectroscopy (CD) measures the differential absorbance of 
polarized light by chiral molecules such as DNA and RNA.  Quadruplex structures 
display characteristic peaks in their CD spectra and the method can be used to 
distinguish between parallel, anti-parallel and hybrid 3+1 type structures (Paramasivan, 
Rujan, and Bolton 2007).  Temperature melts performed at the maximum of peaks in a 
quadruplex CD spectra can be used to make inferences about the stability of the 
secondary structure and the relative effect of bound small molecule ligands (Greenfield 
2006; Paramasivan, Rujan, and Bolton 2007; Weaver et al. 2015). 
 
Summary 
Quadruplex structures represent a promising target for development of novel 
anticancer therapeutics.  The involvement of quadruplexes in many processes 
regulating expression of many oncogenes both at the transcriptional and post-
transcriptional level highlights the potential of these structures as targets.  In addition, 
the roles of quadruplexes in mitochondria and specifically mtDNA are beginning to 
emerge and may provide another avenue for creating targeted therapies for cancer. 
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Mitochondria 
History 
 Mitochondria are central to both energy metabolism and many processes 
governing homeostasis in human cells.  One of the most important functions of 
mitochondria is the role they play in the initiation of the intrinsic pathway of apoptosis.  
Targeting this pathway has become a focus of many scientists as a possible 
mechanism to employ in finding new strategies for causing apoptosis in tumor cells and 
treatment of cancer.  The suggestion that mitochondria may be important in the 
pathogenesis of cancer can be traced back to Nobel laureate Otto Warburg in 1924, 
when first proposed what is now known as the “Warburg effect” (Otto Warburg 1925; 
Liberti and Locasale 2016).  The hypothesis was based on the observation that cancer 
cells have a metabolic shift relative to normal cells where they begin to produce energy 
in the form of ATP primarily by non-oxidative glycolysis rather than through oxidative 
phosphorylation by mitochondria.  (Fulda, Galluzzi, and Kroemer 2010) (Figure 1.7). 
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Figure 1.7 Mitochondria and metabolic reprogramming in cancer 
(Fulda, Galluzzi, and Kroemer 2010) 
Cancer cells shift metabolism to primarily generate ATP through conversion of pyruvate 
to lactic acid rather than by oxidative phosphorylation due to interaction of hexokinase 
directly with VDAC proteins. 
 
  Warburg hypothesized that this shift may be responsible for tumor initiation and 
growth, and if reversed may be a useful strategy to treat cancer.  Although this strategy 
has not been singularly effective overall for treatment of cancer, it has led to discovery 
of other structural and functional abnormalities found in tumor cell mitochondria; and it 
has been demonstrated cancer cells become sensitized to mitochondrial disturbances 
(Fulda, Galluzzi, and Kroemer 2010).  Many of these mechanisms are being utilized in 
currently used, and in developing cancer therapies (Figure 1.8) (Neuzil et al. 2013). 
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Figure 1.8 Mitochondrial targets of anti-tumor agents 
(Neuzil et al. 2013) 
Mitochondrially targeted anticancer drugs, “mitocans”, as classified by Neuzil et al.  
Notably, class 5 and class 8 compounds directed to target the electron transfer chain 
and mitochondrial DNA. 
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Mitochondrial Targets 
Mitochondrial DNA (mtDNA) 
 Mitochondrial DNA (mtDNA) forms a ~17,000 base pair circular genome 
containing approximately 37 genes that code for 2 rRNAs, 22 tRNAs, and 13 
polypeptides.   All of the encoded polypeptides are involved in the electron transport 
chain machinery of the mitochondria (Taanman 1999).  The sensitivity of tumor cells to 
mitochondrial disturbances may be in part due to the increased susceptibility of mtDNA 
to damage, as mitochondria lack efficient DNA repair machinery found in the nucleus 
(Yakes and Van Houten 1997; Berridge, Dong, and Neuzil 2015).  Damage to mtDNA 
has been shown to induce senescence in tumor cells in vivo and, when combined with 
inhibition of mtDNA synthesis, lead to caspase-dependent apoptosis (Laberge et al. 
2013).  In human glioblastoma cells, intact mtDNA has also been shown to be important 
in the process of tumorigenesis and depletion of mtDNA reduces growth in transplanted 
human tumors in vivo in mice (Dickinson et al. 2013). 
 
Electron Transport Chain (ETC) 
The mitochondrial electron transport chain (ETC) is responsible for oxidative 
phosphorylation of pyruvate, using oxygen and cofactors generated in the TCA cycle, to 
phosphorylate ATP from ADP in the mitochondria of cells.  This process relies on five 
enzymatic complexes (Complex I – V) that are located in the mitochondrial inner 
membrane.  The reaction proceeds through reduction of ubiquinone by complex I and II 
using NADH or FADH2 to pass electrons to Complex III.  Complex III then reduces 
cytochrome c to pass electrons to Complex IV, which in turn reduces molecular oxygen 
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to water.  The cascade of reactions in the ETC generates a proton gradient in the 
outward direction relative to the mitochondrial matrix.  The flow of protons back into the 
matrix powers complex V, which uses energy from the proton gradient to produce ATP 
through phosphorylation of ADP using inorganic phosphate.  The proton gradient and 
flow of electrons in the ETC also is responsible for maintaining the negative 
mitochondrial membrane potential (ΔΨm) (Zorova et al. 2018).  Loss of the ΔΨm 
causes cytochrome c release and caspase-9 activation in cells leading to apoptosis in 
tumor cells (Inayat-Hussain et al. 2003).  The flow of electrons in the ETC has another 
consequence, production of reactive oxygen species (ROS) (Figure 1.9) (West, Shadel, 
and Ghosh 2011).  Nominal levels of ROS are important for signaling in healthy cells, 
however excess ROS can damage the cell and also lead to apoptosis.  Due to the 
ability of mitochondria to act as key regulators of the intrinsic apoptotic pathway, there 
has been great interest in the possibility of targeting the ETC to kill tumor cells. 
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Figure 1.9 Sources of reactive oxygen species in the electron transport chain 
(West, Shadel, and Ghosh 2011) 
Electron transport chain protein complexes I – III contribute to generation of reactive 
oxygen species (ROS) in the form of superoxide and hydrogen peroxide. 
 
Complex I 
ETC Complex I, also known as NADH ubiquinone oxidoreductase is responsible 
for transferring electrons from NADH to ubiquinone.  Complex I is located in the inner 
mitochondrial membrane and exists as a large multimeric protein.  The enzyme is a 
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major source of ROS inside the mitochondrial matrix through generation of superoxide.  
Complex I contributes approximately 4 protons per ubiquinone reduced to the outward 
proton gradient from the matrix to the intermembrane space (Lenaz et al. 2006).  
Inhibitors of Complex I such as the common inhibitor Rotenone can enhance its 
capability to produce ROS in the form of superoxide and hydrogen peroxide (Li et al. 
2003).  Rotenone-induced production of ROS has been demonstrated to lead to DNA 
damage and apoptosis in tumor cells through activation of caspase-3 (Liu, Fiskum, and 
Schubert 2002). The diabetes drug Metformin is also being explored for the potential to 
be repurposed as an anticancer therapeutic due to its inhibition of Complex I and the 
downstream effects leading to apoptosis in pancreatic cancer cells (Boukalova et al. 
2016). 
 
Complex II 
Complex II (succinate dehydrogenase) is an approximately 100 kDa hetero-
tetrameric protein located on the inner mitochondrial membrane (Kenney 1975; 
Miyadera et al. 2003; Ralph et al. 2011).  Complex II couples the conversion of 
succinate to fumarate to reduce ubiquinone, which then acts as a carrier to transfer 
electrons to Complex III.  The electrons for succinate oxidation are provided by the 
cofactor FAD, which is reduced to FADH2 in the reaction.  A more complete introduction 
to the Complex II field of study is presented in Chapter 3. 
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Complex III 
The major function of Complex III (NADH:ubiquinone oxidoreductase) is to 
reduce cytochrome c through oxidation of ubiquinol passed from Complex I / II.  This 
process is completed through a pathway termed the “Q-cycle”.  The Q-Cycle is a two-
step process; in the first step the electrons arising from oxidation of ubiquinol are 
transferred through an iron-sulfur cluster to reduce cytochrome c moving 2 H+ to the 
intermembrane space and generating a semiquinone, in the second step a second 
ubiquinol is oxidized and an additional 2 H+ are transferred to the matrix from the 
intermembrane space, reducing the semiquinone back to ubiquinol (Bleier and Dröse 
2013).  Complex III therefore contributes to the ΔΨm, and also has been shown to be a 
major source of ROS in mitochondria (Chen et al. 2003).  Antimycin A is a known 
inhibitor of Complex III, and generates superoxide through electron transfer to molecular 
oxygen (Bleier and Dröse 2013).  Unlike Complex I / II, Complex III can generate ROS 
on either side of the inner mitochondrial membrane, in the matrix or the intermembrane 
space (West, Shadel, and Ghosh 2011). 
 
Complex IV 
Complex IV, known as cytochrome c oxidase, couples the oxidation of 
cytochrome c to the reduction of molecular oxygen to form water.  This process utilizes 
4 H+ from the intermembrane space to reduce oxygen and translocates 4 H+ across the 
inner mitochondrial membrane to the intermembrane space contributing to ΔΨm.  
Altered expression of Complex IV subunits have been observed in colon and prostate 
cancer (Herrmann et al. 2003; K. Zhang et al. 2016).  Complex IV inhibition does not 
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produce ROS directly, however it can indirectly affect the production by other ETC 
complexes through changes in ΔΨm (Lee, Bender, and Kadenbach 2002).  Complex IV 
inhibition also has been shown to suppress mitochondrial respiration and induce 
degradation of HIF-1a in cancer cells.  This was an important finding because HIF-1a is 
essential for adaptive response pathways used by cancer cells to promote angiogenesis 
(Krock, Skuli, and Simon 2011). 
 
Complex V 
Complex V is more well-known as the FoF1-ATPase, and is responsible for 
generating ATP from ADP in the mitochondria.   ATP is synthesized through 
phosphorylation of ADP using inorganic phosphate; the reaction is driven by the ΔΨm 
and movement of H+ back into the mitochondrial matrix.  The movement of H+ through 
the enzyme in the membrane causes a turbine-like rotation of the c-ring portion of the 
protein complex and this rotational energy is utilized to generate ATP from ADP and 
inorganic phosphate.  Inhibition of Complex V does not contribute to significant 
production of ROS, but changes in its activity does have documented roles in cancer 
cells.  Complex V can be inhibited by an oncometabolite 2-HG ((R)-2-hydroxyglutarate), 
which is highly expressed in some gliomas and leukemias.  Complex V inhibition by 2-
HG decreases mitochondrial respiration in U87 glioma cells transfected to express the 
common glioma mutation IDH1(R132H), which increases the amount of 2-HG produced 
in the cell (Fu et al. 2015). 
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Summary 
Targeting mitochondria for treatment of cancer is a growing field due to the 
abundant roles of mitochondria and associated pathways in metabolism, proliferation, 
and apoptosis.  Inhibition of the ETC complexes with drugs such as Metformin and a-
TOS, and adapting their structures to target mitochondria is being explored as a way to 
selectively kill tumor cells (Lan-Feng Dong et al. 2007; L.-F. Dong et al. 2008; Neuzil et 
al. 2013; Boukalova et al. 2016).  Additionally, it has now been observed that some 
currently used cancer drugs such as Cisplatin, previously thought to affect nuclear DNA, 
instead exert their cytotoxicity to tumor cells through interactions with mtDNA 
(Marrache, Pathak, and Dhar 2014; Kohno et al. 2015).  Taken together, this shows the 
significance of continued research focused on targeting mitochondria for development 
of anticancer therapeutics. 
 
NAD(P)H Quinone Oxidoreductase 1 (NQO1) 
NAD(P)H Quinone Oxidoreductase 1 (NQO1) 
A major mechanism proposed for the cytotoxic action of quinolinediones in tumor 
cells involves their reduction by the quinone reduction enzyme known as 
NAD(P)H:quinone oxidoreductase 1 (NQO1).  NQO1 is overexpressed in multiple types 
of tumors; these include brain, breast, liver, lung and colon cancers (Hassani et al. 
2005).  NQO1 can catalyze the two-electron reduction of quinones to hydroquinones.  
The reaction requires cofactors FAD and NAD(P)H to be bound; the reaction proceeds 
through a hydride transfer from NAD(P)H to FAD followed by reduction of the quinone to 
a hydroquinone.  Depending on the stability of the hydroquinone formed, it has been 
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suggested this conversion can cause redox cycling and subsequent generation of 
reactive oxygen species leading to apoptosis in tumor cells both in vitro and in mice 
(Keyari et al. 2013; Ross and Siegel 2017). 
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Hypotheses and Specific Aims 
 
Specific Aim 1:  Characterize the structure of the human c-MYC promoter 
quadruplex; demonstrate interaction of the AIMs with quadruplex DNA structures. 
Hypothesis:  AIMs will stabilize the human c-MYC promoter quadruplex and the 
characterization of the c-MYC quadruplex structure will inform development of more 
potent and selective AIM ligands. 
 
Specific Aim 2:  Measure the cytotoxicity of the AIMs in tumor cells and evaluate 
the mitochondrial mechanism contributing to the antitumor activity of the AIMs. 
Hypothesis:  Current generation AIMs will exhibit improved toxicity to tumor cells.  
Mitochondrial reductases and damage to mitochondria DNA are involved in the 
mechanisms underlying the AIMs antitumor efficacy. 
 
Specific Aim 3:  Examine the cytotoxicity of a novel set of quinolinedione analogs 
in parent breast cancer cells relative to NQO1 overexpressing cells and determine 
the compounds suitability as substrates for NQO1 
Hypothesis:  The set of quinolinediones will exhibit toxicity to the breast cancer cells and 
this will be enhanced in the NQO1 overexpressing cells.  Differential substitutions on the 
quinolinedione analogs will relate to their toxicity in tumor cells and enhance their 
suitability as substrates for NQO1. 
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Abstract 
The c-MYC oncogene mediates multiple tumor cell survival pathways and is 
dysregulated or overexpressed in the majority of human cancers.  The NHE III1 region of 
the c-MYC promoter forms a DNA quadruplex.  Stabilization of this structure with small 
molecules has been shown to reduce expression of c-MYC, and targeting the c-MYC 
quadruplex has become an emerging strategy for development of antitumor compounds.  
Previous solution NMR studies of the c-MYC quadruplex have assigned the major 
conformer and topology of this important target, however, regions outside the G-quartet 
core were not as well-defined.  Here, we report a high-resolution crystal structure (2.35 
Å) of the major quadruplex formed in the NHE III1 region of the c-MYC promoter.  The 
crystal structure is in general agreement with the solution NMR structure, however, key 
differences are observed in the position of nucleotides outside the G-quartet core. The 
crystal structure provides an alternative model that, along with comparisons to other 
reported quadruplex crystal structures, will be important to the rational design of selective 
compounds.  This work will aid in development of ligands to target the c-MYC promoter 
quadruplex with the goal of creating novel anticancer therapies. 
Introduction 
Guanine-rich sequences of DNA and RNA can form a secondary nucleic acid 
structure known as a quadruplex.  Quadruplex motifs have become the subject of 
significant interest due to their presence in human telomeres, 5’-untranstranslated regions 
of mRNA, and in gene promoter regions (Burge et al. 2006).  One such quadruplex-
forming sequence is found in the promoter region of the human c-MYC oncogene.  c-
MYC is estimated to be dysregulated or overexpressed in approximately 70% of all 
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human cancers and is responsible for mediating multiple pathways important in tumor cell 
survival.  Stabilization of the major quadruplex formed in the c-MYC promoter by various 
small molecules has been shown to inhibit transcription of c-MYC thereby reducing 
expression of the oncogene (Siddiqui-Jain et al. 2002; Ou et al. 2007).  This reduction in 
c-MYC expression has been demonstrated to induce apoptosis in multiple types of tumor 
cells (Su et al. n.d.; Brown et al. 2011). Taken together, these findings suggest that the 
c-MYC promoter quadruplex is a promising antitumor target. Several research groups are 
designing small molecules to stabilize the c-MYC promoter quadruplex as a strategy to 
develop potential therapies for treatment of human cancers (Phan, Modi, and Patel 2004; 
Dai et al. 2011; Hu et al. 2018).   
The general sequence motif that forms a quadruplex consists of several short 
guanine repeats (G), separated by short “loop” regions (L) comprised of other nucleotides 
with the overall general sequence of G3-5L<7G3-5L<7G3-5L<7G3-5 (Burge et al. 2006).  
Quadruplexes can form as intramolecular or intermolecular arrangements, consisting of 
single or multiple nucleic acid strands, respectively.  The basic unit of the quadruplex is 
the G-quartet, which is formed as a planar arrangement of four guanine residues held 
together through Hoogsteen bonding and stabilized by a central monovalent cation.  
Multiple G-quartets, usually three or more, stack upon each other to form the quadruplex 
secondary structure and are connected through external loop region nucleotides.  The 
central channel cations are essential for quadruplex formation, with potassium generally 
preferred to sodium.  Potassium cations are observed in a symmetric square antiprismatic 
coordination at the interface of two G-quartets, coordinated by the guanine O6 atoms, 
whereas the relatively smaller sodium atoms display square-planar coordination and are 
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central to a single G-quartet. The species and abundance of these and other cations in 
solution can also serve to influence and stabilize the overall quadruplex topology 
(Bhattacharyya, Mirihana Arachchilage, and Basu 2016).  Quadruplexes can be further 
categorized as parallel, anti-parallel, or hybrid by the types of loops formed and direction 
of the backbone in relation to the G-quartets (Figure 2.1) (Burge et al. 2006). 
 
Figure 2.1 Topology of the c-MYC promoter quadruplex 
Diagram showing fully parallel topology of the c-MYC promoter quadruplex crystal 
structure with all reversal loops continuing in the right to left direction (5’ to 3’).  Thymines 
are represented in yellow, adenines in blue, and guanines in green.  Sequence 
modifications in Pu22 are shown highlighted in red. 
 
Parallel-type quadruplexes are found in promoter regions of c-MYC and several 
other oncogenes that are potential therapeutic targets for cancer including c-KIT, Bcl-2, 
VEGF, and HIF-1α (Siddiqui-Jain et al. 2002; Fernando et al. 2006; Rankin et al. 2005; 
Dexheimer, Sun, and Hurley 2006; Agrawal et al. 2014; Sun et al. 2005; De Armond et 
al. 2005).  The human c-MYC promoter quadruplex is formed under negative supercoiling 
conditions in the nuclease hypersensitivity element III1 region (NHE III1) (Sun and Hurley 
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2009).  NHE III1 is 27 residues in length and responsible for the regulation of 80 - 90% of 
c-MYC oncogene transcription (Pu27) (Ambrus et al. 2005).  Duplex/quadruplex or single-
stranded forms of the NHE III1 region can be bound by transcription factors SP1 or 
CNBP/hnRNP, respectively, to increase c-MYC expression while formation of the 
quadruplex structure prevents transcription (Brooks and Hurley 2009; Raiber et al. 2012).  
NHE III1 contains 20 guanines grouped into five segments of 3 to 4 guanine nucleotides 
separated by one or two adenine or thymine nucleotides.  This guanine-rich character 
allows formation of four possible quadruplex topologies, with the major form being a 
parallel intramolecular quadruplex comprised of the four guanine segments at the 3’-end 
of the sequence (Ambrus et al. 2005).   
In a previous NMR study, it was found that the major biologically relevant 
conformation adopted by the c-MYC promoter quadruplex could be selected from other 
conformers by mutating residues G4, G14 and G23 to thymines and truncating the 
sequence to 22 nucleotides in length (Pu22) (Ambrus et al. 2005).  In a separate NMR 
study, the binding of a quindoline compound with Pu22 and the wild-type Pu27 sequence 
in solution was described (Dai et al. 2011). The latter study revealed the small molecule 
bound in an “induced fit” manner at two sites on the quadruplex, with the 5’ and 3’ flanking 
sequences recruited to form a binding pocket for both the Pu27 and Pu22 sequences.  To 
select the desired biologically relevant conformation, the same Pu22 sequence was 
further utilized in this work to obtain the reported crystal structure. 
 Our interest in obtaining the crystal structure of the c-MYC quadruplex formed by 
Pu22 stemmed from differences previously observed between solution and solid-state 
structures of other quadruplexes in the literature.  Additionally, crystal structures often 
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reveal other important structural information that may be absent in solution, such as the 
involvement of ions or water molecules important to the overall quadruplex topology, or 
potentially relevant quaternary interactions.  On comparison of crystal and solution NMR 
structures of similar quadruplex sequences, differences are sometimes observed in the 
type of cation in the central channel and the overall topology of the quadruplexes.  For 
example, multiple quadruplex topologies have been demonstrated in studies using the 
sequence repeat found in human telomeres, d(GGGTTA).  Solution NMR studies have 
revealed that an anti-parallel quadruplex is formed in the presence of sodium ions, and 
alternatively, a 3+1 hybrid-type quadruplex is observed in solution containing potassium 
ions,  with three parallel strand-edges and one anti-parallel (Wang and Patel 1993; Luu 
et al. 2006; Phan, Kuryavyi, Luu, et al. 2007).  In contrast, the reported crystal structure 
of the same sequence adopts a fully parallel arrangement with potassium cations 
occupying the central channel (Parkinson, Lee, and Neidle 2002).  This parallel topology 
was also shown to be favored in studies of solutions containing molecular crowding 
conditions (Xue et al. 2007; Heddi and Phan 2011).  However, this is not always the case: 
for example, the c-KIT oncogene promoter quadruplex in both solution NMR and crystal 
structures adopts a strictly parallel form containing potassium in the central channel, with 
the position of the nucleotides highly-conserved (Phan, Kuryavyi, Burge, et al. 2007; Wei 
et al. 2012; Wei, Husby, and Neidle 2015).  This led us to question whether the crystal 
structures of other oncogene promoter quadruplexes would be analogous to their NMR 
solution counterparts, or if they would differ significantly as is seen with the telomeric 
sequences. Knowledge of the distinct topology of these quadruplexes is crucial to the 
design of small molecules that stabilize their structures, and there is evidence that subtle 
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differences in structural features could allow for selectivity between specific quadruplex 
targets (Balasubramanian, Hurley, and Neidle 2011; Hu et al. 2018).   
Here, we report a high-resolution crystal structure of the major Pu22 quadruplex 
formed in the human c-MYC promoter and describe several features observed that are 
potentially important for small molecule binding and quadruplex stabilization.  We 
compare the crystal structure of Pu22 with previously reported solution NMR structures 
in an effort to inform future design of quadruplex-targeted compounds (Ambrus et al. 
2005; Yang and Hurley 2006; Dai et al. 2011; Weaver et al. 2015).  In addition, we have 
examined the features of the Pu22 crystal structure in conjunction with other quadruplex 
crystal structures to probe for similar features including positions of ions, water molecules 
and quaternary interactions.  This research aims to aid future development of novel 
quadruplex-targeted compounds and provide information helpful in co-crystallization 
studies with molecules designed to bind the c-MYC promoter and other quadruplex 
structures. 
Materials and Methods 
Crystallization 
The 22-residue DNA oligonucleotide (5’-TGAGGGTGGGTAGGGTGGGTAA-3’) 
was synthesized and purified by Integrated DNA Technologies (standard desalting).  The 
oligonucleotide was diluted into a stock concentration of 10 mM in DNAse/RNAse free 
water and the concentration was determined using a Thermo Scientific NanoDrop 
spectrometer.  The oligonucleotide was then diluted to 2.0 mM in 20 mM sodium 
cacodylate buffer at pH 6.5 containing 30 mM KCl and annealed by heating for 10 minutes 
at 95° C and cooled overnight at 4° C prior to crystallization experiments. Initial crystal 
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screening was done in a 96-well plate format using an Art Robbins Instruments 
GRYPHON liquid-handling crystallization robot.  Various precipitants (PEGs, 2-Methyl-
2,4-pentanediol (MPD)) were screened along with varying concentrations of salts (NaCl, 
KCl, LiCl etc.) as previously outlined (Campbell and Parkinson 2007). Crystals used for 
diffraction data collection were grown in a 24-well plate format using the hanging-drop 
vapor diffusion technique with 300 mM KCl, 50 mM LiCl, and 22.5% MPD in 50 mM 
sodium cacodylate at pH 6.5 with a 1:1 ratio of oligonucleotide to reservoir solution.  
Crystals were harvested using the reservoir solution or additional MPD (30%) as a cryo-
protectant and flash cooled in liquid nitrogen for storage prior to data collection.   
Data collection and refinement 
Initial diffraction screening was performed using a Rigaku MicroMax 007HF X-ray 
generator with VariMax HighFlux optic and R-AXIS IV image plate detector. Diffraction 
data for structure determination were taken at the Stanford Synchrotron Radiation 
Lightsource (SSRL) beam line 12-2.  The native dataset was collected at a wavelength of 
0.9793 Å over a 360° range with 0.2° rotation per image.  Data were processed using 
XDS with autoxds script at SSRL (Kabsch 2010).   These data were analyzed using 
Xtriage in Phenix prior to phasing (Adams et al. 2010).  Initial phases were obtained by 
molecular replacement using Phaser in Phenix using the truncated guanine decks of a 
CKIT-1 promoter quadruplex as a search model (PDBID: 4WO2) (Wei et al. 2012).  An 
improved, complete model was constructed through iterative cycles of refinement, 
phasing, and manual model building using Phenix and Coot, respectively (Emsley et al. 
2010).  Refinement was performed in Phenix refine, followed by submission to the PDB 
Redo webserver (Joosten et al. 2014).  The structure obtained from the PDB Redo 
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webserver was then re-refined in Phenix refine with simulated annealing and randomized 
atomic displacement parameters to reduce any potential bias in Rfree.  The final structure 
was refined in Phenix using data from 34.91 – 2.35 Å with a final Rwork, Rfree of 0.220 and 
0.245, respectively (Table 2.1).  Atomic coordinates and structure factors are deposited 
in the RCSB Protein Databank with ID 6AU4 (Berman et al. 2000).  Visualization and 
RMSD calculations were performed using Pymol (http://www.pymol.org) (Schrodinger 
2015). Pearson correlation coefficient (CC) was calculated by randomly assigning the 
experimental reflection data to two half-datasets (x, y) as described by Karplus and 
Diederichs (Table 2.1) (Karplus and Diederichs 2012). 
Circular dichroism spectroscopy 
Circular dichroism spectra were measured using a Jasco J-810 spectropolarimeter 
or on a Chirascan CD spectrophotometer at room temperature in a quartz cuvette with a 
10 mm or 4 mm pathlength for sample A or B, respectively.  The oligonucleotide sample 
was made at 2 µM concentration with 300 mM KCl, 50 mM LiCl, and 22.5% MPD in a 50 
mM sodium cacodylate buffer at pH 6.5 to mimic the crystallization conditions (A) or at 5 
µM in 10 mM potassium phosphate buffer pH 6 to replicate the conditions used in previous 
studies (Paramasivan, Rujan, and Bolton 2007; Dai et al. 2011) (B). The solutions were 
annealed by heating to 95° C for 10 minutes and cooled overnight to 4° C prior to data 
collection.  
Results 
The 22 residue c-MYC promoter sequence Pu22 crystallized in the P21212 space 
group in a stacked dimer formation with two parallel, single-stranded quadruplex 
structures per asymmetric unit (Table 2.1 and Figure 2.1).  The two independent 
 52 
quaduplexes (A, B) are structurally similar with the majority of the core guanine-residue 
positions being maintained between the strands (G4-G6A/B, G8-G10A/B, G13-G15A/B, and 
G17-G19A/B RMSD = 0.190 Å).  Each individual quadruplex contains three loops and a 
5’-head and 3’-tail region.  The 5’-head region consists of residues T1-G2-A3 and is 
observed stretched away from the central G-quartets with the residues roughly orthogonal 
relative to the core guanines.  The two related 5’-head regions appear in a quasi-mirror-
related arrangement with the related atomic positions maintained (T1-G2-A3A/B, RMSD = 
0.568 Å).  The 3’-tail regions of the two quadruplexes in the asymmetric unit are 
comprised of residues T20-A21-A22 and are positioned below and approximately planar 
to the central G-quartets.  The quadruplex structure also contains three double-chain 
reversal propeller-type loops, with two consisting of single thymine residues (T7, T16) that 
flank a third, two-residue loop (T11-A12). These regions display less similarity between 
quadruplex A and B, owing predominately to the loop formed by residues T11 and A12 
(T7A/B, T16A/B, and T11-A12A/B RMSD = 2.182 Å).  All of the loops, the head, and the tail 
regions are involved in interactions important for the crystal packing.  Electron density is 
also observed for a non-channel potassium ion and several water molecules. 
 
Table 2.1 Data collection and refinement statistics 
Sequence 5’-TGAGGGTGGGTAGGGTGGGTAA-3’ 
Data Collection  
    Space group P 21 21 2 
    Unit cell dimensions (a, b, c) (Å) α, β, γ (°) 65.7 69.8 33.0 90 90 90 
    Wavelength (Å) 0.9793 
    Resolution (Å)* 34.91 – 2.35 (2.43 – 2.35) 
    Total reflections* 85280 (8398) 
    Unique reflections* 6774 (652) 
    Multiplicity*  12.6 (12.9) 
    Completeness (%)* 99.4% (99.7%) 
    I/σ* 33.9 (4.4) 
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    Wilson B-factor (Å2) 58.8 
    Rmeas†* 0.042 (0.605) 
    CC1/2‡* 1.000 (0.966) 
Refinement  
    Resolution (Å)* 34.91 – 2.35 (2.53 – 2.35) 
    Rwork§* 0.220 (0.319) 
    Rfree§* 0.245 (0.322) 
    Macromolecules 2 
    DNA Residues 44 
    Total Atoms 956 
    Potassium ions 6 
    Waters 16 
    Average Overall B-factor (Å2) 80.2 
    Average B-factor DNA Residues (Å2) 80.7 
    Average B-factor Potassium Ions (Å2) 53.1 
    Average B-factor Waters (Å2) 59.7 
    RMS (bonds) (Å) 0.009 
    RMS (angles) (°) 1.08 
    TLS groups 2 
PDB ID 6AU4 
*Statistics in parentheticals are for the high-resolution shell 
† 𝑅#$%& = 	
∑ * ++,-∑ |/0(234)6/(̅234)|
+
08-9:;
∑ ∑ /0(234)+08-9:;
, where Ii(hkl) is the ith observation of the intensity of the 
reflection hkl and n is the multiplicity. 
§ 𝑅<=>3 = 	
∑ ||?@AB|6|?CD;C||9:;
∑ |?@AB|9:;
, where Fobs and Fcalc are the observed and calculated structure-factor 
amplitudes for each reflection hkl.  𝑅E>$$ was calculated with 10% of the diffraction data that were 
selected randomly and excluded from refinement. 
‡CC1/2 is the intra-dataset Pearson correlation coefficient (CC) calculated by randomly assigning 
the experimental reflection data to two half-datasets (x, y).  𝐶𝐶 = 	 ∑ (G06G̅)6	
+
08- (H06HI)
*∑ (G06G̅)	+08-
J*∑ (H06HI)	+08-
J
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Figure 2.2 Crystal structure of c-MYC quadruplex 
Side-view (A) and top-view (B) of the crystal structure of the c-MYC promoter quadruplex 
formed by Pu22, guanine bases in green, thymine in yellow, adenine in blue.  Potassium 
ions in purple (two shown positioned behind strand backbones), waters in red.  
Orange/cyan backbone coloring represents strand A and B, respectively. 
 
Potassium ions 
Each individual quadruplex contains two potassium ions at the centers of two 
stacked G-quartets and an additional potassium ion similarly positioned at the interface 
that forms the dimer in the asymmetric unit, for a total of five potassium ions in the central 
cavity (Figure 2.2).  The positions of these potassium ions relative to the G-quartets is 
consistent with that reported for other quadruplex crystal and NMR structures (Yang and 
Hurley 2006; Phan, Kuryavyi, Burge, et al. 2007).  The ions central to the G-quartets are 
observed in symmetric square antiprismatic coordination with the O6 atoms of the 
guanine residues, as expected, with an average bond distance of 2.65 Å.  An additional 
potassium ion is positioned between two adjacent symmetry-related strand B 
quadruplexes, interacting with O4 oxygen of T7 of one and backbone phosphate of G9 of 
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the other (Figure 2.3B).  This ion is also observed in close proximity (< 3.7 Å) to three 
additional water molecules.  This additional potassium ion was placed following careful 
consideration of each of the other components present in the crystallization conditions. 
 
Figure 2.3 Crystal packing and non-channel potassium ions 
Packing arrangement in the unit cell of c-MYC promoter quadruplex crystal structure 
formed by Pu22, coloring scheme same as Figure 2.2; black box indicates region shown 
in Figure 2.3B (A). Non-channel potassium ions interact with residues T7 and G9 (B). 
 
Packing interactions 
The Pu22 c-MYC promoter quadruplex structure displays several interesting 
packing interactions that induce a more elongated conformation than that observed for 
the same sequence by solution NMR.  The two quadruplex strands, A and B, π–π stack 
together at the G-quartets near their 5’-ends with the G-quartets containing residues G4, 
G8, G13, and G17 of each quadruplex interacting to create the extended dimer structure 
(Figure 2.2).  Residues T1-G2-A3 from the 5’-head of four quadruplexes in the lattice, 
two of A and two of B, form stacked structures stretched away from the central G-quartets, 
with base pairing between T1A/T1B, G2A/G2B and G3A/G3B (Figure 2.4A). 
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Figure 2.4 Packing interactions 
Quaternary interaction of four 5’-head regions (T1-G2-A3); each color represents a 
separate symmetry-related strand (A).  Stacked helical structure formed between 3’-tail 
regions of (T20-A21-A22) in the crystal lattice (B). 
 
This exposes the G-quartet composed of residues G4, G7, G12, and G17, allowing 
the stacking of the two quadruplexes head-to-head in the asymmetric unit (Figure 2.2). 
Residues T20-A21-A22 from the 3’-tail of the two quadruplexes, A and B, interact forming 
a near-planar double helical structure (Figure 2.4B).  Residue T20A/B and A22A/B form 
Watson-Crick base pairs with slightly elongated hydrogen bonds and A21A and A21B are 
involved in an apparent π-stacking interaction. 
Conserved water molecules 
Two water molecules were observed in nearly identical positions in each of the 
independent quadruplexes formed by strand A and B (Figure 2.5). The conserved 
positions of these waters suggests their presence may be important in stabilizing the 
quadruplex secondary structure.  The first water is seen interacting with O4’ of residue 
G6, OP1 of G8 and N2 of G5.  The second water is seen in interaction with N2/N3 of 
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residue G8 and O4’ of G9.  These waters were placed based on the presence of 
positive density observed in the difference map.  More bound waters of this type may be 
present, however, the high B-factor of the data did not allow for confident placement of 
additional atoms even at this near-atomic resolution. 
 
Figure 2.5 Conserved water molecules 
Water molecules in conserved positions between strand A and B of the c-MYC promoter 
crystal structure (only strand A shown as an example), 2Fo-Fc map shown contoured at 
1.0 σ. 
 
Comparison of the crystal and solution structures of Pu22 
The overall topology of the crystal structure is consistent to that reported for the 
same sequence by solution NMR with several notable differences (Table 2.2, 
PDB:1XAV).  The most striking difference between the solution and crystal structure is 
observed in the T1-G2-A3 region at the 5’-head of the quadruplexes (Figure 2.6). In the 
NMR structure, these residues lay stacked on top of the G-quartet composed of residues 
G4, G7, G12, and G17. ((Ambrus et al. 2005, 20015), PDB: 1XAV).  In contrast, in the 
crystal structure this 5’-head region is observed extended and the top, nearest, G-quartet 
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is the interface where the dimer is formed. The difference in this region in comparison to 
the NMR structure is also likely responsible for the high RMSD observed in the position 
of loop residue T7 and differences in the general shape of the phosphate backbone in 
this region.  The 3’-tail region is also extended, albeit to a lesser degree, away from the 
G-quartet comprised of residues G6-G10-G15-G19 in the crystal structure in comparison 
to the NMR structure.  The difference in the position of loop residue T16 can also likely 
be attributed to this extended conformation that is involved in crystal packing interactions. 
 
Table 2.2 RMSD of strand A of Pu22 (PDB: 6AU4) to published DNA quadruplex 
structures 
RMSD (Å)    
 c-MYC (NMR, PDB: 
1XAV) 
c-KIT (X-ray, PDB: 
4WO2) 
HTelo (X-ray, PDB: 
4FXM) 
G-quartets* 1.36 6.65 1.03 
T1-G2-A3 (5’-head) 4.16 - - 
T20-A21-A22 (3’-tail) 3.45 - - 
T7, T11-A12, T17 
(loop) 
4.34 - - 
Overall 7.31 10.38 2.78 
*G-quartets are comprised of G4-G5-G6, G8-G9-G10, G13-G14-G15, and G17-G18-G19.  RMSD 
comparisons were not made between distinct quadruplex structures (c-KIT, telomeric) for the 
loop, head and tail regions due to significant sequence differences. 
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Figure 2.6 Comparison to NMR solution structure 
Overlay of NMR solution structure (PDB:1XAV, grey) with strand A (orange) and strand 
B (cyan) of the c-MYC promoter crystal structure, side view (A), top view (B). 
 
To examine the effect of the crystallization conditions on the conformation of Pu22, 
we performed circular dichroism spectroscopy at conditions analogous to those used in 
solution NMR studies (Dai et al. 2011).  Parallel quadruplex structures display 
characteristic peaks at approximately positive 265 nm and negative 240 nm in their CD 
spectra (Burge et al. 2006).  The parallel topology was confirmed for the Pu22 
oligonucleotide under both the conditions used in the solution NMR studies as well as at 
the crystallization conditions to provide additional evidence the conformation observed in 
the crystal structure is not an artifact of the crystallization environment (Figure 2.7). 
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Figure 2.7 Circular dichroism spectroscopy 
CD spectra of the Pu22 oligonucleotide under crystallization conditions (A) or conditions 
previously reported to form the parallel c-MYC promoter quadruplex (B). 
 
Comparison to other crystal structures 
The human c-KIT promoter region also contains a quadruplex sequence motif, and 
its crystal structure has some distinct similarities and differences to the c-MYC quadruplex 
formed by Pu22 (Figure 2.8A and Table 2.2, PDB: 4WO2).  In both crystal structures, a 
quadruplex dimer forms the asymmetric unit, with the G-quartets closest to the 5’-region 
observed in a stacked formation.  The c-KIT strands (A & B) forming the dimer are rotated 
one guanine relative to one another (approximately 90°), whereas the c-MYC strands (A 
& B) are rotated two guanines relative to one other (approximately 180°).  This causes 
the c-KIT quadruplex loop region nucleotide C9A to occupy the same space as loop 
nucleotide A12A of the c-MYC quadruplex, and this is regardless of the additional T11A 
present in this loop region of the c-MYC structure.  The loop nucleotide C9B of c-KIT 
superimposes with loop nucleotide T7B of the c-MYC quadruplex.  The c-MYC quadruplex 
structure contains a non-channel potassium ion interacting with residues T7 and G9.  A 
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non-channel potassium ion is also observed at an unrelated site in the c-KIT crystal 
structure interacting with residues A16 and G17.   
 
Figure 2.8 Comparison to other quadruplex crystal structures 
Overlay of c-KIT crystal structure (PDB:4WO2, grey) with strand A (orange) and strand B 
(cyan) of the c-MYC promoter crystal structure; loop residue labels correspond to c-MYC 
crystal structure (A).  Overlay of human telomeric crystal structure (PDB: 4FXM, grey, 
ligand not shown) with strand A (orange) of the c-MYC promoter crystal structure (B).   
 
Several crystal structures of the fully parallel quadruplex formed by the human 
telomeric repeat sequence in complex with a small molecule ligand have been reported, 
including an example of the intramolecular arrangement at 1.65 Å (Figure 2.8B, PDB: 
4FXM) (Nicoludis et al. 2012).  The telomeric quadruplex forms a dimer with both strands 
reported as identical in the asymmetric unit.  The telomeric structure is remarkably similar 
to the Pu22 c-MYC quadruplex with the exception of the loop regions.  In the c-MYC 
structure, these loops are formed by one or two nucleotides, whereas the telomeric 
structure contains loops made of three nucleotides each.  However, even with this 
difference in loop region length, the c-MYC quadruplex can be superimposed on the 
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telomeric quadruplex with an RMSD of only 2.78 Å (Table 2.2, PDB: 4FXM).  Interestingly, 
the Watson-Crick packing interaction seen with the T20-A21-A22 tail of two c-MYC 
quadruplexes is also observed in the crystal structure of the telomeric quadruplex, but 
between two loop regions containing residues T11-A13 and A1, suggesting that a 3’-
terminal TAA sequence may be useful for crystallization of other quadruplexes (Nicoludis 
et al. 2012). 
During preparation of this manuscript, a 3.8 Å structure was reported of a 
sequence modified c-MYC promoter quadruplex in complex with the DEAH/RNA helicase 
DHX36 (Chen et al. 2018).  In the reported complex structure, it is suggested quadruplex 
destabilization by the helicase results in a one-residue shift of the nucleotides involved in 
formation of the three G-quartets, causing the quartet nearest to the 5’-head region to be 
reformed by G4, G8, A12, and T16.  This finding is noteworthy, however, due to the low-
resolution of the structure and rearrangement observed in the presence of the helicase, 
it did not appear relevant for comparison with our crystal structure. 
Discussion 
In this manuscript we report a high-resolution crystal structure of the major 
quadruplex formed in the promoter region of the human c-MYC oncogene.  The overall 
topology is in general agreement with the previously published solution NMR structures, 
with the major differences occurring predominately in the head and tail regions of the 
sequence and not in the central G-quartet structure (Ambrus et al. 2005; Dai et al. 2011).  
This is important as it strengthens the validity of previous and ongoing computational and 
synthetic studies that have used the NMR solution structures as a guide. 
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The more exposed G-quartets observed in the crystal structure, in comparison to 
those reported using solution NMR, confirm both the flexibility of the head and tail regions 
of the promoter sequence and the rigid nature of the G-quartets in this quadruplex.  This 
could be biologically relevant as the flanking regions would not be terminal residues in 
genomic DNA and are likely able to project away from the G-quartets as is observed in 
the crystal structure (Figure 2.2).  This will be important in future studies with the goal of 
developing small molecule ligands to bind the c-MYC quadruplex.  For example, in the 
solution NMR study of a small molecule interaction with the c-MYC promoter quadruplex, 
it was observed that part of the ligand binding pocket involved nucleotides in the 5’-head 
(A3) and 3’-tail regions (T20, A21) (PDB: 2L7V, (Dai et al. 2011)).  It is possible, as 
suggested by the c-MYC quadruplex crystal structure, that these residues are not in close 
proximity to provide such interactions in the biological setting as illustrated schematically 
in Figure 2.1.  In this scenario, the reported “induced fit” mode of ligand binding would 
require major structural rearrangement and be less energetically favorable.  Therefore, 
an alternative strategy would be to design ligands with a binding mode that takes 
advantage of the more linearized conformation of the head and tail regions, potentially 
affording tighter binding and selectivity for the c-MYC quadruplex.  This alternative binding 
hypothesis will be a crucial consideration in the future design of c-MYC quadruplex-
targeted small molecule ligands. 
The packing interactions observed in the crystal highlight the importance of the 
loop, head and tail regions of the sequence to allow for crystal formation and will be 
generally helpful in optimizing quadruplex sequences for crystallization.  The Watson-
Crick bonding observed at the 3’-tail of the Pu22 sequence also suggests a preference 
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for nucleotides not involved in the G-quartet core region to follow the normal B-DNA base 
pairing paradigm even in very close proximity to the G-quartets. However, there is 
previous evidence that these flanking regions may remain single-stranded under 
conditions of negative supercoiling (Sun and Hurley 2009). 
Comparison of the c-MYC quadruplex crystal structure to the c-KIT quadruplex and 
the human telomeric quadruplex show the majority of differences occur in the head, tail 
and loop regions.  Differences in the length of loop regions and position of the loop 
nucleotides will provide useful tools for designing ligands that would be selective for 
specific quadruplex structures as has been suggested previously (Neidle 2017; Hu et al. 
2018).  Overall, this work has provided the basis for ongoing co-crystallization studies 
with the Pu22 c-MYC promoter quadruplex and our set of novel quadruplex ligands, the 
anthracenyl isoxazole amides (AIMs) (Han et al. 2009; Weaver et al. 2015).  These 
findings will also be of benefit to other researchers in their efforts to target the c-MYC 
promoter and other therapeutically relevant quadruplex targets. 
Accession number 
Atomic coordinates and structure factors for the reported crystal structures have been 
deposited with the Protein Data bank under accession number 6AU4. 
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Figure S.2.1 G-quartet potassium ions 
Example of square antiprismatic coordinated potassium ions central to two stacked G-
quartets in the crystal structure  
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Abstract 
 The anthracenyl isoxazole amides (AIMs) are a novel class of compounds 
previously demonstrated to have significant antitumor activity.  The AIMs interact with 
quadruplex DNA structures and are being investigated as quadruplex-ligands designed 
to treat human cancers.  Previous studies have examined the interaction of the AIMs 
with quadruplex DNA using methods including fluorescence spectroscopy, mass 
spectrometry, and computational modeling.  In this work we provide evidence of the 
interaction of the AIMs with quadruplex-forming DNA sequences found in the human c-
MYC promoter region and in human telomeres.  The interaction of the AIMs with 
quadruplex DNA and the consequent increase in the stability of these structures is 
examined through circular dichroism thermal melting studies and by 1H NMR. 
 
Introduction 
Anthracenyl Isoxazole Amides (AIMs) 
 The class of compounds known as the anthracenyl isoxazole amides (AIMs) are 
synthesized in the Natale laboratory at the University of Montana.  The AIMs have 
previously been submitted to the National Cancer Institute 60 cell line panel (NCI60) 
and demonstrated significant activity in multiple cancer cell lines.  A subsequent 
COMPARE analysis of the NCI60 revealed that the AIMs mechanism of action did not 
correlate significantly with any known agents in the database (Han et al. 2009).  
Additional studies showed the compounds had a preference toward quadruplex DNA 
structures relative to the B-form found in duplex DNA.  Computational modeling has 
also been previously performed to develop a potential structure activity relationship for 
 69 
the AIMs with quadruplex sequences found in human telomeres and in oncogene 
promoters.  This led to design of the current generation of AIM compounds by the 
Natale laboratory. The general structure of the AIMs consists of a hydrophobic 
anthracene region connected through an isoxazole-pyrrole scaffold to two alkyl amine 
tails, with a variable substitution at the 10-position of the anthracene (Figure 2.9).  This 
includes a variety of double-tail AIM analogs, including the 10-Chloro and 10-Phenyl 
AIMs, which have been reported to have low- and sub-micromolar antitumor activity in 
SNB-19 glioblastoma cells (Han et al. 2009; Weaver et al. 2015). 
 
Figure 2.9 Structure of the anthracenyl isoxazole amides (AIMs) 
Structure of the anthracenyl isoxazole amides (AIMs) demonstrating the double-tail 
tertiary alkyl amines, isoxazole pyrrole scaffold, and the hydrophobic anthracene region 
with variable substitutions at the 10-position. 
 
In this work, we demonstrate the interactions of the 10-Chloro and 10-Phenyl 
AIMs with quadruplex DNA structures using circular dichroism (CD) and NMR 
spectroscopy.  Thermal melting curves were measured in the presence of the AIMs to 
determine their effect on the stability of various quadruplex sequences and topologies.  
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In addition, 1H NMR spectra were acquired to examine interactions of quadruplexes with 
the AIMs through chemical shift measurements of readily identifiable peaks in the imino 
region of the spectra that are observed for quadruplex structures. 
Methods 
Circular Dichroism 
Oligonucleotide Sequences 
Pu22: 5’-TGAGGGTGGGTAGGGTGGGTAA-3’ 
HTelo: 5’-TTAGGGTTAGGGTTAGGGTTAGGG-3’ 
mt9438: 5’-GGCGTAGGTTTGGTCTAGGG-3’ 
CSB II: 5’-AAGGGGGAGGGGGGGTTTrGrGrGrArA-3’ (r prefix means RNA base) 
 
c-MYC Promoter Sequence & Human Telomeric Sequence (Pu22 & HTelo) 
Oligonucleotides were added to pH 6 10 mM potassium phosphate buffer to make 
a 1 mM DNA stock solutions. Samples were made using previously made 5 mM stock 
solutions of AIM compounds in DMSO. Three independent samples were made at 5 µM 
strand concentration in pH 6 10 mM potassium phosphate buffer for the oligonucleotide 
strands alone and oligonucleotides plus 2 equiv. compounds. Samples were annealed by 
heating to 90 °C for 10 minutes and then gradually cooling to 4 °C overnight prior to data 
collection. 
CD spectra and thermal melting curves were acquired using an Applied 
Photophysics Chirascan CD Spectrophotometer. CD spectra were gathered from 200 nm 
– 400 nm with a 1 nm bandwidth and 0.2 nm step-size at 5 °C and 0.5 seconds time-per-
point. CD thermal melting curves were gathered at 295 nm (HTelo) or 265 nm (Pu22) 
 71 
from 10 °C – 90 °C at a rate of 1 °C/min in 0.5 °C steps. The CD thermal melting curves 
were acquired at 24 seconds time-per-point with 1 nm bandwidth. 
 
Mitochondrial COX I Sequence (mt9438) 
Samples were made using previously made 5 mM stock solutions of AIM 
compounds in DMSO. Three independent samples were made at 4 µM strand 
concentration in 20 mM potassium phosphate buffer for the oligonucleotide alone or with 
4 equiv. of the AIM compounds. Samples were annealed by heating to 90 °C for 10 
minutes and then gradually cooling to 4 °C overnight prior to data collection. 
CD spectra and thermal melting curves were acquired using a Jasco J-810 
spectropolarimeter. CD spectra were gathered from 220 nm – 350 nm.  CD thermal 
melting curves were gathered at 290 nm 10 °C – 60 °C at a rate of 1 °C/min in 0.1 °C 
steps. 
 
Mitochondrial CSB II Sequence (CSB II) 
Samples were made at 2 µM strand concentration in 10 mM potassium phosphate 
buffer at the desired pH for the oligonucleotide alone or with 1 equiv. of the AIM 
compound. Samples were annealed by heating to 90 °C for 10 minutes and then gradually 
cooling to 4 °C overnight prior to data collection. 
CD spectra and thermal melting curves were acquired using a Jasco J-810 
spectropolarimeter. CD spectra were gathered from 200 nm – 400 nm.  CD thermal 
melting curves at pH 6 were gathered at 265 nm 60 °C – 90 °C at a rate of 1 °C/min in 
0.5 °C steps.  CD thermal melts of pH 4, 8, 9 were gathered at varying temperature ranges 
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due to intermittent issues with the temperature controller, however all covered the range 
of interest, determined to be 50 °C – 80 °C. 
 
Data Analysis 
Following data collection, thermal melting curves were fit to a six-parameter logistic 
curve using the qpcR package for the R statistical computing software environment (R 
Core Team, 2014; Spiess, 2014).  The six-parameter logistic fit was chosen to minimize 
the number fitting parameters while maximizing goodness-of-fit using criteria such as AIC, 
BIC and R2. Thermal melting values (Tm) for each condition were assigned by computing 
the minimum value of the first derivative of the fitted curve for each sample. A statistical 
analysis between the sample groups was then conducted where appropriate using the 
ANOVA method in R and additionally a post-hoc Tukey’s range test. 
 
NMR Spectroscopy 
 The Pu22 sample was made at a concentration of 1 mM oligonucleotide in 10 
mM potassium phosphate buffer at pH 6 in H2O containing 10% D2O.  The HTelo 
sample was made at a concentration of 2.5 mM oligonucleotide in 100 mM potassium 
phosphate buffer at pH 6 in H2O containing 10% D2O.  Spectra were taken using water 
suppression techniques on a 500 MHz Varian NMR as described previously (Weaver et 
al. 2015). 
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Results 
Circular Dichroism Spectroscopy 
 In these studies, we examined the interaction of the AIMs with multiple quadruplex-
forming DNA sequences using circular dichroism spectroscopy (CD).  First, we collected 
a CD spectra of the quadruplex formed in the c-MYC promoter using the Pu22 
oligonucleotide sequence with and without two equivalents of the 10-Chloro or 10-Phenyl 
substituted AIMs in solution.  The CD spectra of the Pu22 oligonucleotide confirmed the 
presence of a fully parallel quadruplex topology, demonstrated by the characteristic peaks 
at approximately +265 nm and -240 nm.  The obtained spectra also display a 
hypsochromic shift in the presence of the AIMs (Figure 2.10).  To determine if interaction 
of the AIMs would affect the stability of the quadruplex structure, we performed thermal 
melting studies near the CD signal maxima (265 nm).  The presence of both the 10-Chloro 
and 10-Phenyl AIMs created a noticeable right shift of the thermal melting curves (Figure 
2.11).  Next, we calculated the melting temperature (Tm) of the curves as defined by 
maximum slope of the curve.  This revealed that the presence of the 10-Chloro and the 
10-Phenyl AIMs in solution caused a statistically significant increase in the Tm for the 
quadruplex structure formed by Pu22 of 3.2° C and 2.1 C°, respectively (Figure 2.12).  
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Figure 2.10 Circular dichroism spectra of Pu22 oligonucleotide 
Circular dichroism spectra of Pu22 oligonucleotide with and without two equivalents of 
AIM compounds in solution. Pu22 only (blue), 10-Chloro (orange), and 10-Phenyl (grey). 
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Figure 2.11 Thermal melting curves of the Pu22 oligonucleotide 
Circular dichroism thermal melting curves of the Pu22 oligonucleotide taken at 265 nm 
with and without two equivalents of AIM compounds in solution.  Pu22 only (blue), 10-
Chloro (orange), and 10-Phenyl (grey). 
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Figure 2.12 Statistical analysis of Pu22 thermal melting 
Tm change induced by two equivalents of both the 10-Chloro AIM (P = 0.00008) and 10-
Phenyl AIM (P = 0.0008) compared to Pu22 alone (ANOVA P = 9.5E-05).  Post-hoc 
testing also reveals a difference between Tm 10-Chloro AIM and 10-Phenyl AIM at two 
equivalents (P = 0.02).  Error bars represent 95% confidence intervals for three 
independent samples (n=3).  Tukey’s post-hoc test used for comparisons between 
groups.  Symbols represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***). 
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Next, we repeated the above series of studies using the same conditions with the 
sequence known to form quadruplex structures in human telomeres (HTelo).  The HTelo 
oligonucleotide displayed peaks at +295 nm and -240 nm with a shoulder at 
approximately +270 nm, consistent with the expected mixed 3+1 quadruplex topology.  
The 10-Chloro and 10-Phenyl AIMs both cause a similar hypsochromic shift as previously 
observed for the Pu22 sequence (Figure 2.13) (Weaver et al. 2015).  Additionally, the 
shoulder region observed in the spectra of HTelo alone at approximately 270 nm 
appeared to shift left in the presence of the 10-Phenyl AIM.  Thermal melting experiments 
with the HTelo sequence also demonstrated a right-ward shift in the presence of both 
AIMs (Figure 2.14).  Analysis of the melting curves indicated the presence of the 10-
Chloro and 10-Phenyl AIMs increased the Tm of the quadruplex formed by the HTelo 
sequence by 3.3° C for both compounds (Figure 2.15) (Weaver et al. 2015). 
  
 78 
 
Figure 2.13 Circular dichroism spectra of HTelo oligonucleotide 
Circular dichroism spectra of HTelo oligonucleotide with and without two equivalents of 
AIM compounds in solution. HTelo only (green), 10-Chloro (orange), and 10-Phenyl 
(grey). (Weaver et al. 2015) 
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Figure 2.14 Thermal melting curves of the HTelo oligonucleotide 
Circular dichroism thermal melting curves of the HTelo oligonucleotide taken at 295 nm 
with and without two equivalents of AIM compounds in solution.  HTelo only (green), 10-
Chloro (orange), and 10-Phenyl (grey). (Weaver et al. 2015) 
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Figure 2.15 Statistical analysis of HTelo thermal melting 
Tm change induced by two equivalents of both the 10-Chloro AIM (P = 0.002) and 10-
Phenyl AIM (P = 0.002) compared to HTelo alone (ANOVA P = 0.0009).  Error bars 
represent 95% confidence intervals for three independent samples (n=3).  Tukey’s post-
hoc test used for comparisons between groups.  Symbols represent significance levels 
(P < 0.05 *, P < 0.01 **, P < 0.001 ***). (Weaver et al. 2015) 
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We then similarly measured the effect of the AIMs on two sequences that form 
quadruplex structures in mitochondrial DNA (mt9438 & CSB II).  The mt9438 
oligonucleotide displays peaks characteristic of a fully anti-parallel quadruplex (+290 
nm, -260 nm).  The 10-Phenyl AIM did not create a significant shift in the spectra even 
at four equivalents of compound in solution (Figure 2.16).  No right-ward shift was 
observed in the thermal melting curves measured in the presence of either of the 10-
Chloro or 10-Phenyl AIM (Figure 2.17).  This was verified by comparison of the Tm 
calculated for each curve, which demonstrated there was no statistically significant 
change observed in the presence of the AIMs (Figure 2.18). 
The CSB II oligonucleotide displayed peaks at +265 nm and -240 nm, indicating 
a fully parallel quadruplex topology.  A hypsochromic shift was observed for the CSB II 
spectra in the presence of one equivalent of the 10-Phenyl AIM (Figure 2.19).  
However, we were unable to calculate a Tm for this sequence to determine the effect of 
the AIMs, as the CSB II sequence is remarkably stable and could not be unfolded even 
at 90° C (Figure 2.20).  Due to this finding, we also performed pH titrations and found 
the CSB II quadruplex is able to form in solutions with a wide-range of pH’s from 4 – 9 
(Figure 2.21).  Additional melting studies with the CSB II quadruplex in pH 4 – 9 
solutions confirmed its resistance to temperature melting even under these variable 
conditions (Figure 2.22). 
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Figure 2.16 Circular dichroism spectra of mt9438 oligonucleotide 
Circular Dichroism spectra of mt9438 oligonucleotide with and without four equivalents of 
AIM compounds in solution. mt9438 only (dark blue) and 10-Phenyl (grey). 
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Figure 2.17 Thermal melting curves of the mt9438 oligonucleotide 
Circular dichroism thermal melting curves of the mt9438 oligonucleotide taken at 290 nm 
with and without four equivalents of AIM compounds in solution.  mt9438 only (blue), 10-
Chloro (orange), and 10-Phenyl (grey). 
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Figure 2.18 Statistical analysis of mt9438 thermal melting 
No significant change in Tm was observed with four equivalents the 10-Chloro AIM and 
10-Phenyl AIM compared to mt9438 alone.  Error bars represent 95% confidence 
intervals for three independent samples (n=3).   
25
27
29
31
33
35
37
39
Te
m
pe
ra
tu
re
 (°
C
) 
mt9438 Thermal Melting Summary
mt9438 4 eq. 10'Chloro AIM 4 eq. 10'Phenyl AIM
 85 
 
Figure 2.19 Circular dichroism spectra of CSB II oligonucleotide 
Circular Dichroism spectra of CSB II oligonucleotide with and without one equivalent of 
10-Phenyl AIM in solution. CSB II only (yellow) and 10-Phenyl (grey). 
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Figure 2.20 Thermal melting curves of the CSB II oligonucleotide 
Thermal melting curves of the CSB II oligonucleotide at 265 nm with and without one 
equivalent of 10-Phenyl AIM.  CSB II only (yellow) and 10-Phenyl (grey). 
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Figure 2.21 Circular dichroism spectra of CSB II oligonucleotide in varying pH solutions 
-10
-5
0
5
10
15
20
225 245 265 285 305 325 345
M
ill
id
eg
re
es
Wavelength (nm)
CSB II CD Spectra
pH 4 pH 6 pH 8 pH 9 pH 10 pH 12
 88 
 
Figure 2.22 Thermal melting curves of the CSB II oligonucleotide in varying pH 
solutions  
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NMR Spectroscopy 
The authors would like to acknowledge Matthew J. Weaver of the Natale laboratory, and 
Dr. Earle Adams at the University of Montana for their contributions to these experiments. 
 We examined interactions of the AIMs with quadruplex DNA using nuclear 
magnetic resonance spectroscopy (NMR).  The 1H NMR spectra for the Pu22 
oligonucleotide displayed shifts in the anisotropy observed for protons in the key imino 
region in the presence of two equivalents of the 10-Phenyl AIM (Figure 2.23).  The peaks 
for the Pu22 sequence have been previously assigned, and this will allow for insight into 
the precise interactions between the AIMs and the c-MYC promoter quadruplex.  This 
analysis is currently being performed by the Natale laboratory and will be reported on in 
a subsequent publication. 
Shifts in the imino region were also observed for the HTelo oligonucleotide at two 
equivalents of the 10-Chloro AIM in solution (Figure 2.24) (Weaver et al. 2015).  The 
peaks for this sequence are less well-defined, owing to the existence of an equilibrium of 
folded and unfolded states as reported previously (Luu et al. 2006).   
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Figure 2.23 NMR spectra of the Pu22 oligonucleotide 
Comparison of the imino proton region of the 1H NMR spectra for the quadruplex formed 
by the human c-MYC promoter sequence (Pu22) in the presence and absence of two 
equivalents of the 10-Phenyl AIM.  Chemical shifts in ppm.  Pu22 alone (blue), 10-Phenyl 
AIM (green). 
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Figure 2.24 NMR spectra of the HTelo oligonucleotide 
Comparison of the imino proton region of the 1H NMR spectra for the quadruplex formed 
by the human telomeric (HTelo) sequence in the presence and absence two equivalents 
of the 10-Chloro AIM.  Chemical shifts in ppm.  HTelo alone (blue), 10-Chloro AIM (green). 
(Weaver et al. 2015) 
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Discussion 
In this study we demonstrated that the AIMs stabilize multiple quadruplex DNA 
structures in solution using both NMR and CD.  The hypsochromic shifts observed in 
spectra the Pu22, HTelo, and CSB II sequences in the presence of the AIMs is similar to 
that observed for other quadruplex binding ligands (Zhou et al. 2005; Freyer et al. 2007; 
Paramasivan, Rujan, and Bolton 2007) (Figures 2.10, 2.13, and 2.19).  In addition, the 
10-Chloro and 10-Phenyl AIMs were shown to stabilize the quadruplex structure formed 
by both the Pu22 and HTelo sequences as demonstrated by increases in the Tm of the 
structures measured by CD spectroscopy (Figures 2.12 and 2.15).  The Pu22 and HTelo 
quadruplexes are examples of mixed 3+1 and parallel topologies, respectively.  In 
contrast, no significant change in melting temperature was observed for the anti-parallel 
quadruplex formed by the mt9438 sequence found in mitochondrial DNA (Figure 2.18).  
This suggests the AIMs could have selectivity between distinct quadruplex topologies and 
their binding could be affected by the type of loops present in the specific quadruplex 
structure.  This is an important finding as the field has expressed both curiosity and 
skepticism regarding the possibility of selectively targeting specific quadruplex sequences 
or topologies (Burge et al. 2006; Neidle 2017).  The high melting point of the CSB II 
DNA:RNA hybrid quadruplex structure did not allow for characterizing the effect of the 
AIMs on its stability.  However, it was shown that the hybrid quadruplex is remarkably 
resistant to changes in temperature and pH, and it was confirmed that the chimeric 
sequence did form a parallel quadruplex as expected.  The stability of the CSB II 
quadruplex is likely due to the incorporation of the RNA nucleotides, as recent reports 
indicate RNA quadruplexes are generally more stable than their DNA counterparts (Fay, 
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Lyons, and Ivanov 2017).  This is consistent with previous studies that suggest a helicase 
is involved in resolution of the CSB II hybrid quadruplex in cells, as the structure is unlikely 
to spontaneously resolve under physiological conditions (Wanrooij et al. 2012).  Our 
studies using solution 1H NMR also demonstrated the interaction of the AIMs for both the 
Pu22 and HTelo oligonucleotides as indicated by shifts in the peaks observed for the 
imino region of the spectra.   
Overall, this work will significantly contribute to the continued development of the 
AIMs as quadruplex-targeted ligands.  The CD experiments provide the basis for 
efficiently screening future generations of AIM compounds with various quadruplex-
forming sequences.  Additional analysis of the NMR experiments is underway by the 
Natale laboratory and should reveal insights about the precise interactions between the 
AIMs and quadruplex DNA. 
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Abstract 
 Mitochondria are regulators of many important processes in cells including 
metabolism and apoptosis.  Targeting mitochondria to induce the intrinsic pathway of 
apoptosis is being examined in the field of anticancer drug design as a way to kill tumor 
cells for treatment of cancer.  One strategy involves inhibition of the electron transfer 
chain (ETC) of mitochondria causing loss of the mitochondrial membrane potential  
(ΔΨm) and leading to apoptosis in tumor cells.  In this study we provide evidence for a 
mitochondrial mechanism of action for a novel set of antitumor compounds, the 
anthracenyl isoxazole amides (AIMs), mediated by their inhibition of the ETC.  We first 
demonstrate that the AIMs can inhibit ETC protein complexes, specifically Complex II, 
using spectrophotometric assays and provide an initial binding hypothesis for the 
interaction of the AIMs with Complex II using computational molecular docking.  We 
also show that treatment with the AIMs leads to rapid damage in mitochondrial DNA 
(mtDNA) and an associated reduction in mtDNA copy number.  Further, we confirm a 
dose-dependent loss of the ΔΨm and induction of the intrinsic pathway of apoptosis in 
glioblastoma cells following treatment with the AIMs. 
 
Introduction 
 Mitochondria are crucial regulators of many homeostatic processes in cells and 
are responsible for both energy metabolism and as gatekeepers to the intrinsic pathway 
of apoptosis.  Targeting mitochondria to induce apoptosis in tumor cells has been the 
focus of many researchers with the goal of developing new anticancer therapeutics 
(Fulda, Galluzzi, and Kroemer 2010).  Multiple agents that act on the mitochondria have 
been demonstrated to have selective toxicity to tumor cells (Neuzil et al. 2013). 
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Targeting mitochondria could be especially advantageous when developing 
therapeutics as they are present throughout all types of human cancers; therefore a 
mitochondrial-targeted agent could be more universally applicable in contrast to 
targeting a mutation or gene expression pattern specific to only a smaller subset of 
cancers (Neuzil et al. 2013).  
One strategy employed to target mitochondria is perturbation of the electron 
transport chain (ETC).  The ETC refers to five protein complexes (Complex I – V) that 
are located in the inner mitochondrial membrane and responsible for the generation of 
cellular ATP through oxidative phosphorylation.  Complex I (NADH ubiquinone 
oxidoreductase) converts ubiquinone to ubiquinol using NADH to pass electrons to 
Complex III.  Similarly, Complex II passes electrons to Complex III through reduction of 
ubiquinone to ubiquinol coupled with oxidation of succinate to fumarate.  Due to the high 
electron flow through Complexes I, II, and III, all of these represent sites of significant 
reactive oxygen species (ROS) production as superoxide and hydrogen peroxide (Liu, 
Fiskum, and Schubert 2002; St-Pierre et al. 2002; Indo et al. 2007; West, Shadel, and 
Ghosh 2011).  Complex IV and V are not major contributors to the production of ROS, 
however they have also been explored as potential mitochondrial targets of antitumor 
agents (Lee, Bender, and Kadenbach 2002; Fu et al. 2015).   
Complex II has several known inhibitors, and they fit into two groups, those that 
bind at one of two ubiquinone sites (Up and Ud) or those that bind at the succinate site.  
Some examples of known ubiquinone site inhibitors include thenoyltrifluoroacetone 
(TTFA), Atpenin 5 (AA5), and carboxin (Miyadera et al. 2003).  Ubiquinone is held in the 
binding pocket through a hydrogen bonding interaction with residue Tyr-D83.  As the 
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reaction proceeds, hydrogen bonds are formed between His-B207 and Ser-C27, 
ubiquinone is then reduced to ubiquinol and leaves the binding pocket (Sun et al. 2005).  
It is thought that the His-207B allows flow of electrons from the 3Fe-4S iron-sulfur 
cluster in Complex II (Horsefield et al. 2006).  Inhibitors of Complex II at the ubiquinone 
site can take the place of ubiquinone in the binding pocket, preventing reduction of 
ubiquinone (Sun et al. 2005).  The result of this is an increase in ROS, partially due to 
leak of electrons in the mitochondrial matrix and loss of succinate to fumarate 
conversion.  It has also been suggested that Complex II inhibition can cause an 
increase in ROS generation by Complex I through a reverse electron flow mechanism.  
The evidence for this is a reduction in the amount of ROS produced by Complex II 
inhibition in the presence of rotenone, a potent inhibitor of Complex I (Ralph et al. 
2011).  The increase in ROS has been demonstrated to induce apoptosis in multiple 
types of tumor cells (L.-F. Dong et al. 2008; Byun et al. 2008; Ralph et al. 2011; Wang 
et al. 2016).  Inhibition of Complex II specifically, using the known ubiquinone site 
inhibitor TTFA, has been shown to delay cell cycle progression by prolonging G1, S and 
G2/M phases, as well as causing oxidation of glutathione (Byun et al. 2008).  Another 
set of studies with TTFA demonstrated an increase in autophagy in cancer and 
transformed cells following treatment, and this was mediated through ROS (Chen et al. 
2007).  The vitamin E analog a-Tocopheryl succinate (a-TOS) is yet another example of 
a Complex II inhibitor that disrupts ubiquinone binding, generating superoxide and 
ultimately causing apoptosis in tumor cells (Sun et al. 2005; L.-F. Dong et al. 2008).  In 
the case of a-TOS and a targeted derivative “MitoVES”, this toxicity has been shown to 
be selective for tumor cells relative to normal endothelial cells and to inhibit tumor 
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angiogenesis in vivo in mice (L.-F. Dong et al. 2008).  The ROS generated by Complex 
II inhibition is exacerbated by damage to mtDNA, and increased mitochondrial ROS can 
cause damage to mtDNA and ETC proteins (Indo et al. 2007; Byun et al. 2008; 
Alexeyev et al. 2013).  Additionally, mtDNA depleted transformed endothelial cells were 
shown to be resistant to apoptosis induced by a-TOS, suggesting mtDNA damage may 
mediate induction of apoptosis following inhibition of Complex II (Lan-Feng Dong et al. 
2007).  Together, these studies highlight the importance of exploring Complex II as a 
potential target for development of selective antitumor agents. 
The anthracenyl isoxazole amides (AIMs) are a class of compounds synthesized 
in the laboratory of Nicholas Natale at the University of Montana.  The AIMs structure 
consists of three major regions, the alkyl amine tails, the isoxazole pyrrole scaffold and 
the anthracene ring system.  The compounds explored in this work also contain a 
variable substitution at the 10-position of the anthracene (Figure 3.1).  Substitutions of 
electron-rich moieties at the 10-position have been demonstrated to improve the 
antitumor cell efficacy of these compounds (Weaver et al. 2015). 
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Figure 3.1 Structure of the anthracenyl isoxazole amides (AIMs) 
Structure of the anthracenyl isoxazole amides (AIMs) demonstrating the double-tail 
tertiary alkyl amines, isoxazole pyrrole scaffold, and the hydrophobic anthracene region 
with variable substitutions at the 10-position. 
 
The generation of compounds that are the focus of this work are referred to as 
the “double-tails”, referencing the addition of the two alkyl amine chains which has 
improved the pharmacokinetic properties and toxicity of these molecules over previous 
generations (Han et al. 2009; Weaver et al. 2015).  The AIMs have previously 
demonstrated significant antitumor activity in a National Cancer Institute 60 human 
cancer cell line panel (NCI60) and sub-micromolar efficacy in human glioblastoma cells, 
specifically (Gajewski et al. 2009; Han et al. 2009; Weaver et al. 2015).  The 
mechanism underlying the activity of the AIMs against these cancer lines could not be 
determined by an NCI60 COMPARE analysis as they did not correlate significantly with 
any agents of known mechanism of action.  The AIMs have also previously been 
studied as ligands for quadruplex DNA, as our laboratory has demonstrated the 
interaction with these secondary structures (Han et al. 2009; Weaver et al. 2015).  The 
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focus of this work is to characterize a mitochondrial mechanism of action for the AIMs 
that contributes to their antitumor activity in glioblastoma cells. 
Dr. Alison K. Kearns of the Beall laboratory first demonstrated the possibility of a 
mitochondrial modulated mechanism of apoptosis induced by the AIMs in glioblastoma 
cells (Kearns 2013).  This included the observation that AIMs appeared to localize to 
mitochondria of cells and that treatment with AIMs caused a subsequent increase in 
mitochondrial ROS (Kearns 2013).  Initially, our cell viability studies with the AIMs relied 
on using MTT reduction as an indicator of AIM cytotoxicity, however MTT results can 
depend partially on involvement of mitochondrial reductases (Mosmann 1983; Berridge, 
Herst, and Tan 2005; Fedotcheva et al. 2017; Rai et al. 2018).  Careful examination of 
our previous data and the methods used led us to the hypothesis that the AIMs may be 
acting through interactions with the electron transport chain or mitochondrial DNA. 
To explore this further, this work evaluated the two most potent AIM compounds, 
the 10-Biphenoxy and 10-Phenyl analogs, in an effort to determine the mechanism 
underlying their effect on mitochondria in cells.  We also performed confocal imaging 
experiments with glioblastoma cells treated with AIMs and a mitochondrial-specific 
fluorescent dye to confirm localization of the AIMs to mitochondria.  Next, we employed 
a lactate dehydrogenase (LDH) activity assay as a measure of cell viability that is not 
dependent on mitochondrial reductases. 
Comparison of the LDH results with our MTT data led us to consider the AIMs 
could be inhibiting activity of mitochondrial reductases and as a result display lower 
measured toxicity in the LDH assay.  To test this hypothesis, we employ activity assays 
of several ETC protein complexes to measure the inhibitory activity of the AIMs.  For 
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this purpose, we utilize several commercially available kits to measure the inhibitory 
effect of the AIMs on ETC complexes isolated using specific antibodies (complexes I, II 
and IV) and in intact mitochondria (complexes II + III) as described previously (Lai et al. 
2013).  Additionally, we perform molecular docking calculations to explore the potential 
of the AIMs as ubiquinone site inhibitors at Complex II.  We also examine whether 
treatment with the AIMs increased mtDNA damage and reduced copy number as would 
be expected to occur alongside an increase in mitochondrial ROS due to inhibition of 
ETC complexes (Yakes and Van Houten 1997; Indo et al. 2007; Phillips, Sprouse, and 
Roby 2014).  For this purpose, we use a previously reported method to accurately 
measure changes in mtDNA damage and copy number (Chan and Chen 2009; Chan et 
al. 2012).  Analysis of glioblastoma cells treated with AIMs by flow cytometry allows for 
measurement of the expected downstream effects of inhibition of ETC activity.  With this 
method we measured changes in ΔΨm using the mitochondrial redox sensor JC-1.  Our 
analysis using JC-1 includes both the classic approach and an alternative approach that 
utilizes an alternative excitation at 405 nm to better distinguish JC-1 aggregates from 
monomers (Perelman et al. 2012).  With this method, we were able to define 
populations of “hyperpolarized” mitochondria, which we defined as cells with greater 
mitochondrial update of the JC-1 dye due to increased ΔΨm (Giovannini et al. 2002; 
Perelman et al. 2012).  We also measured activation of caspase-9 and caspase- 3/7 as 
indicators of activation of the intrinsic apoptotic pathway.  Finally, we demonstrate 
induction of apoptosis in the glioblastoma cells using Annexin-V and propidium iodide. 
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Methods 
Cell Culture 
SNB-19 Human Glioblastoma 
SNB-19 (American Type Cell Culture Cat No. CRL-2266) were grown in RPMI-
1640 medium with 10% FBS, 2 mM L-Glutamine, and Penicillin Streptomycin added.  
Cells were grown under optimal growth conditions (37° C, 5% CO2, humidified 
atmosphere) to approximately 90% confluence before use in experiments. 
 
C6 Rat Glioma 
C6 rat glioma cells were obtained as a gift from the Patel laboratory at the 
University of Montana.  The cells were grown in RPMI-1640 medium with 10% FBS, 2 
mM L-Glutamine, and Penicillin Streptomycin added.  Cells were grown under optimal 
growth conditions (37° C, 5% CO2, humidified atmosphere) to approximately 90% 
confluence before use in experiments. 
 
E-18 Primary Rat Astrocytes 
Primary E-18 astrocytes taken from the hippocampus and cortex of Sprague-
Dawley rats were given to us by the Jackson Laboratory at the University of Montana.  
The cells were grown in BrainBitsâ NbASTROâ medium under optimal growth 
conditions (37° C, 5% CO2, humidified atmosphere) prior to use. 
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MTT Cell Viability Assay 
Cells were washed with PBS (2 mL) and then treated with Trypsin EDTA (2 mL) 
to detach cells from culture flask prior to counting with a Coulter counter.  Cells were 
diluted to 10,000 cells / mL and plated on a 96-well plate with 100 µL per well (1000 
cells / well).  Cells were grown in optimal growth conditions and allowed to adhere 
overnight. Treatment solutions were prepared in growth medium at varying 
concentrations using a 5 mM compound stock solution prepared previously in sterile 
DMSO.  Medium was removed from the 96-well plate via aspiration and treatment 
solutions were added as outlined (Table 3.1).  Cells were grown in treatment medium 
for 24 hours and then treatment medium was removed via aspiration and 100 µL of 
untreated growth medium was added to each well.  Cells were then allowed to grow for 
a four-day growth period.  Following the growth period, 50 µL of MTT solution (1 mg/mL 
in growth medium) was added to each well and the 96-well plate was placed on a plate 
shaker for 5 minutes to mix.  The plate was then incubated at growth conditions for 4 
hours before removing medium/MTT solution from the wells carefully via aspiration to 
avoid disturbing the formazan crystals.  One hundred µL of DMSO was then added to 
each well and the plate was placed on a plate shaker for 5 minutes to dissolve the 
crystals.  A SpectraMax 190 plate reader was used to measure the absorbance of the 
wells at 562 nm. 
Table 3.1 Example 96-well plate layout for MTT assay 
Column: #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 
Treatment: 
No 
Cells 
DMSO 
Control 
5 nM 
 
10 nM 
 
25 nM 50 nM 100 nM 250 nM 500 nM 1 µM 2.5 µM 5 µM 
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Data Analysis 
IC50 values were calculated using the ‘R’ statistical computing software and the 
‘ic50’ package (R Core Team, 2014; Frommolt, 2010).  This package fits a logistic 
model to the dose-response data collected using the MTT assay and approximates the 
concentration of the compound required to inhibit the growth of the cells by 50% versus 
the DMSO control (IC50). 
 
LDH Cell Viability Assay 
LDH cytotoxicity assays were performed using a commercially available kit 
(PierceÔ LDH Cytotoxicity Kit #88953).  The assays were carried out according to the 
manufacturer protocol.  Cells were plated in sterile 96-well plates at approximately 
7,500 cells / well in 100 µL medium (RPMI-1640 with 10% FBS, L-Glutamine, and 
Penicillin-Streptomycin added for SNB-19 & C6 cells; BrainBitsâ NbASTROâ for 
primary rat astrocytes).  Cells were incubated overnight at optimal growth conditions to 
allow them to adhere to the bottom of the wells.  Cells were treated by removing 
medium and adding treatment medium containing DMSO vehicle or AIMs at the desired 
concentration and incubated 24 hours at growth conditions (Table 3.2).  Forty-five 
minutes prior to the end of the 24-hour incubation, 10 µL of lysis buffer (10x) was added 
to each of the maximum LDH release wells and the plates were placed back in the 
incubator to finish the 24-hour treatment period.  Following treatment, 50 µL of medium 
from each well was transferred to a second 96-well plate and 50 µL of the LDH reaction 
solution was added to each well.  These plates were then incubated again at growth 
conditions for 30 minutes in the dark.  Fifty µL of stop solution was added to each well to 
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halt the LDH reaction and plates were measured at 490 nm and 680 nm using a 
SpectraMax 190 plate reader to measure LDH activity as formazan formation and 
background absorbance, respectively. 
 
Data Analysis 
IC50 values were calculated using the ‘R’ statistical computing software and the 
‘ic50’ package (R Core Team, 2014; Frommolt, 2010).  This package fits a logistic 
model to the dose-response data collected using the LDH assay and approximates the 
concentration of the compound required to inhibit the growth of the cells by 50% versus 
the DMSO control (IC50).   
 
Table 3.2 96-well plate layout for LDH assay 
Column: #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 
Treatment: 
No 
Cells 
Medium 
Only 
DMSO 
Control 
 
0.1 µM 
 
0.25 µM 0.5 µM 1 µM 2.5 µM 5 µM 10 µM 25 µM 
Maximum 
LDH 
Release 
 
Confocal Microscopy 
Cells were washed with PBS (2 mL) and then treated with Trypsin EDTA (2 mL) 
to detach cells from culture flask prior to counting with a Coulter counter.  Cells were 
diluted to 100,000 cells / mL and plated on an 8-well Lab-Tek II chambered coverglass 
slide at a density of 20,000 cells / well in 0.2 mL growth medium.  Cells were grown in 
optimal growth conditions and allowed to adhere overnight.  The following day, 
treatment medium was made by dilution of 5 mM DMSO stock solutions of AIM 
compounds in growth medium.  Culture medium was removed by aspiration and 
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treatment medium containing the desired compound was added.  The cells were then 
incubated at growth conditions 10 minutes prior to removing treatment medium by 
aspiration.  Each well was washed with 0.2 mL of PBS twice prior to addition of staining 
solution.  For mitochondrial staining, 0.2 mL of 100 nM MitoTracker™ DeepRed FM 
(Invitrogen™) in culture medium was added prior to a second incubation under the 
previous conditions for 45 minutes.  Following staining, the solutions were removed by 
aspiration and each well was washed twice with 0.2 mL of PBS.  Cells were then fixed 
in 4% PFA, prepared fresh the previous day, for 10 minutes on ice prior to imaging.  
Imaging was completed on an Olympus FV-1000 confocal laser scanning microscope 
immediately following fixation.  Images were captured using a 60x oil-immersion 
objective lens (NA 1.42).  Compound fluorescence was captured using selective 
excitation at 405 nm and emission collected at 422 nm.  MitoTracker™ fluorescence 
was measured at an excitation of 635 nm and emission at 688 nm. 
 
Image Processing 
Confocal images were processed using Fiji and ImageJ (Schindelin et al. 2012, 
2015).  Contrast was adjusted using image LUT to match intensity of the compound 
fluorescence to the MitoTracker™, avoiding oversaturation of regions of interest.  The 
StackReg plugin was used to perform a translation, scaling, and rotation alignment of 
images to correct for chromatic aberration observed in the images due to the large 
difference in emission wavelengths of the compound versus the Mitotracker (422 nm vs. 
668 nm, respectively) (Thevenaz, Ruttimann, and Unser 1998).  Images were filtered 
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using the “Unsharp Mask” function of ImageJ.  The unprocessed images are available 
upon request. 
ETC Inhibition Assays 
Complex I 
Complex I inhibition was measured using a commercially available kit (Abcam 
MitoToxä Complex I OXPHOS Activity Assay #ab109903) according to the 
manufacturer protocol.  Bovine heart mitochondria (BHM) were solubilized through 
addition of 40 µL of the supplied detergent to 360 µL of BHM and mixture by vortex.  
The solubilized BHM were incubated on ice for 30 minutes and then centrifuged at 
25,000 x g for 20 minutes at 4° C.  The supernatant was collected, and the pellet 
discarded prior to adding 5 mL of Mito Buffer.  Fifty µL of the above solution was then 
added to each well of a provided 96-well plate pre-coated with Complex I specific 
antibodies and incubated for two hours at room temperature.  Following incubation, the 
solution was removed from the wells by inversion and blotting of the plate on a Kimwipe.  
Each well was washed with 300 µL of Wash Solution and subsequently inverted and 
blotted a second time.  Forty µL of provided phospholipids were then added to each well 
and the plate was covered and incubated for 45 minutes at room temperature.   
AIM compound solutions were made by diluting 32.4 µL of a 5 mM DMSO stock 
solution into a total volume of 1.8 mL of the provided Complex I activity solution to 90 
µM and then performing serial dilutions to achieve 900 µL of each desired 
concentration.  Rotenone solutions were made similarly using a 10 µM DMSO stock 
diluted in 1.8 mL of Complex I activity solution to 0.125 µM and then performing serial 
dilutions to achieve 900 µL of each desired concentration.  DMSO controls were made 
 113 
using 16.2 µL of DMSO in Complex I activity solution to a final volume of 900 µL to 
match the maximum DMSO concentration of the above AIMs solutions. 
Following the 45-minute incubation, 200 µL of compound diluted in Complex I 
activity solution was added to each well of the plate as outlined (Table 3.3).  Output was 
immediately measured as absorbance at 340 nm on a SpectraMax M4 microplate 
reader in kinetic mode, taking a reading once per minute for 2 hours at 30° C. 
 
Table 3.3 Layout of Complex I 96-well plate 
Rows ↓ 1 2 3 4 5 6 7 8 9 10 11 12 
A – D 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
E – H 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  0.125  0.063  0.031  0.016  0.008  DMSO 
10-Biphenoxy in blue, 10-Phenyl in yellow, Rotenone in green. 
 
Data Analysis 
The reaction rate was calculated as the change in absorbance per minute 
(mOD/min).  This rate was calculated in the linear phase of the assay (0 – 4000 
seconds) as determined by the fitted linear curves with the goal of achieving 
approximately R2 of 0.99 for each well as per the manufacturer protocol.  Row A + H do 
not contain the Complex I specific antibodies and therefore were used as “background” 
rates which were averaged and subtracted from the calculated rates prior to fitting the 
IC50 curves.  The IC50 for each compound was calculated using the R statistical 
computing software with the package “drc” (R Core Team, 2014; Ritz et al., 2015).  The 
data was fit to a three-parameter logistic curve and the IC50 was defined as the 
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concentration required to reach 50% inhibition of the activity of the DMSO control 
samples.  Data was visualized in R using the package “ggplot2”. 
Complex II 
Complex II inhibition was measured using a commercially available kit (Abcam 
MitoToxä Complex II OXPHOS Activity Assay #ab109904) according to the 
manufacturer protocol.  Bovine heart mitochondria (BHM) were solubilized through 
addition of 36 µL of the supplied detergent to two 360 µL samples of BHM and mixture 
by vortex.  The solubilized BHM were incubated on ice for 30 minutes and then 
centrifuged at 25,000 x g for 20 minutes at 4° C.  The supernatant was collected, and 
the pellet discarded prior to adding 20 mL of Buffer Solution.  200 µL of the above 
solution was then added to each well of a provided 96-well plate pre-coated with 
Complex II specific antibodies and incubated for two hours at room temperature.  
Following incubation, the solution was removed from the wells by inversion and blotting 
of the plate on a Kimwipe.  Each well was washed with 300 µL of Wash Solution and 
subsequently inverted and blotted a second time. 
AIM compound solutions were made by diluting 32.4 µL of a 5 mM DMSO stock 
solution into a total volume of 1.8 mL of the provided Complex II activity solution to 90 
µM and then performing serial dilutions to achieve 900 µL of each desired 
concentration.  DMSO controls were made using 16.2 µL of DMSO in Complex II activity 
solution to a final volume of 900 µL to match the maximum DMSO concentration of the 
above AIMs solutions. 
200 µL of compound diluted in Complex II activity solution was added to each 
well of the plate as outlined (Table 3.4).  Output was immediately measured as 
 115 
absorbance at 600 nm on a SpectraMax M4 microplate reader in kinetic mode, taking a 
reading once per minute for 1 hour at room temperature. 
 
Table 3.4 Layout of Complex II 96-well plate 
Rows ↓ 1 2 3 4 5 6 7 8 9 10 11 12 
A – D 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
E – H 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
10-Biphenoxy in blue, 10-Phenyl in yellow. 
 
Data Analysis 
The reaction rate was calculated as the change in absorbance per minute 
(mOD/min).  This rate was calculated in the linear phase of the assay (720 – 3000 
seconds) as determined by the fitted linear curves with the goal of achieving 
approximately R2 of 0.99 for each well as per the manufacturer protocol.  Row A + H do 
not contain the Complex II specific antibodies and therefore were used as “background” 
rates which were averaged and subtracted from the calculated rates prior to fitting the 
IC50 curves.  Column 6 was excluded from the analysis for both compounds as the 
activity in this entire column contained outliers in the dose-response curve fits as 
determined by the residual standard error and residual plots of the fits.  The IC50 for 
each compound was calculated using the R statistical computing software with the 
package “drc” (R Core Team, 2014; Ritz et al., 2015).  The data was fit to a three-
parameter logistic curve and the IC50 was defined as the concentration required to reach 
50% inhibition of the activity of the DMSO control samples.  Data was visualized in R 
using the package “ggplot2”. 
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Complex II + III 
Complex II + III inhibition was measured using a commercially available kit 
(Abcam MitoToxä Complex II + III OXPHOS Activity Assay #ab109905) according to 
the manufacturer protocol.  The Complex II + III activity solution was made using 12 mL 
of the succinate solution, 500 µL of the oxidized cytochrome C solution, 120 µL of 0.2 M 
KCN and 15.2 µL of 10 mM rotenone as per the manufacturer protocol. 
AIM compound solutions were made by diluting 16.6 µL of a 5 mM DMSO stock 
solution into a total volume of 920 µL of the Complex II + III activity solution to 90 µM 
and then performing serial dilutions to achieve 460 µL of each desired concentration.  
DMSO controls were made using 8.3 µL of DMSO in Complex II + III activity solution to 
a final volume of 460 µL to match the maximum DMSO concentration of the above AIMs 
solutions.  Antimycin A solutions were made by diluting 11.5 µL of a 10 µM antimycin A 
DMSO stock solution to 0.125 µM and then performing serial dilutions to achieve 460 µL 
of each desired concentration. 
One hundred-twenty µL of BHM was diluted into 880 µL of Complex II + III Mito 
Buffer and 20 µL of this solution was rapidly added to the solutions containing the 
Complex II + III activity solutions and compounds.  The solutions were mixed rapidly 
and 100 µL was transferred to the 96-well plate as outlined below for rows B, C, D and 
E, F, G (Table 3.5).  The output was measured immediately as absorbance at 550 nm 
on a SpectraMax M4 microplate reader in kinetic mode, with a measurement every 20 
seconds for 10 minutes at room temperature. 
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Table 3.5 Layout of Complex II + III 96-well plate 
Rows ↓ 1 2 3 4 5 6 7 8 9 10 11 12 
A – D 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
E – H 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  0.125  0.063  0.031  0.016  0.008  DMSO 
10-Biphenoxy in blue, 10-Phenyl in yellow, Antimycin A in green. 
 
Data Analysis 
The reaction rate was calculated as the change in absorbance per minute 
(mOD/min).  This rate was calculated in the linear phase of the assay (0 – 400 seconds) 
as determined by the fitted linear curves with the goal of achieving approximately R2 of 
0.99 for each well as per the manufacturer protocol.  Row A + H do not contain the BHM 
and therefore were used as “background” rates which were averaged and subtracted 
from the calculated rates prior to fitting the IC50 curves.  Column 6 was excluded from 
the analysis for the 10-Phenyl AIM and column 11 was excluded from the analysis for 
the 10-Biphenoxy AIM and antimycin A as the volume in these wells was double the 
volume of the other reaction wells due to the serial dilutions performed.  The IC50 for 
each compound was calculated using the R statistical computing software with the 
package “drc” (R Core Team, 2014; Ritz et al., 2015).  The data was fit to a three-
parameter logistic curve and the IC50 was defined as the concentration required to reach 
50% inhibition of the activity of the DMSO control samples.  Data were visualized in R 
using the package “ggplot2”. 
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Complex IV 
Complex IV inhibition was measured using a commercially available kit (Abcam 
MitoToxä Complex IV OXPHOS Activity Assay #ab109907) according to the 
manufacturer protocol.  300 µL of Blocking Solution was added to each well of the 
provided 96-well plate pre-coated with Complex IV specific antibodies and incubated at 
room temperature for 1 hour.  Bovine heart mitochondria (BHM) were solubilized 
through addition of 10 µL of the supplied detergent to 90 µL of BHM and mixture by 
vortex.  The solubilized BHM were incubated on ice for 30 minutes and then centrifuged 
at 25,000 x g for 20 minutes at 4° C.  The supernatant was collected and kept on ice 
until use.  The 96-well plate was emptied by inversion and blotted with a Kimwipe prior 
to a second addition of 300 µL blocking solution to each well.  The plate was emptied 
and blotted a second time.  Twenty µL of solubilized BHM solution was diluted into 22 
mL of Mito Buffer.  Twenty µL of the above solution was then added to each well of a 
provided 96-well plate pre-coated with Complex IV specific antibodies and incubated for 
3 hours at room temperature.  Following incubation, 300 µL of Mito Buffer was added to 
each well to wash and then the solution was removed from the wells by inversion and 
blotting of the plate on a Kimwipe.  Each well was washed with 300 µL of Wash Solution 
and subsequently inverted and blotted a second time. 
AIM compound solutions were made by diluting 32.4 µL of a 5 mM DMSO stock 
solution into a total volume of 1.8 mL of the provided Complex IV activity solution to 90 
µM and then performing serial dilutions to achieve 900 µL of each desired 
concentration.  DMSO controls were made using 16.2 µL of DMSO in Complex II activity 
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solution to a final volume of 900 µL to match the maximum DMSO concentration of the 
above AIMs solutions. 
Two hundred µL of compound diluted in Complex IV activity solution was added 
to each well of the plate as outlined (Table 3.6).  Output was immediately measured as 
absorbance at 550 nm on a SpectraMax M4 microplate reader in kinetic mode, taking a 
reading once per minute for 1 hour at room temperature. 
 
Table 3.6 Layout of Complex IV 96-well plate 
Rows ↓ 1 2 3 4 5 6 7 8 9 10 11 12 
A – D 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
E – H 
(µM Conc.) 
90  45  22.5  11.25  5.625  2.813  1.406  0.703  0.352  0.176  0.088  DMSO 
10-Biphenoxy in blue, 10-Phenyl in yellow. 
 
Data Analysis 
The reaction rate was calculated as the change in absorbance per minute 
(mOD/min).  This rate was calculated in the linear phase of the assay (600 – 2400 
seconds) as determined by the fitted linear curves with the goal of achieving 
approximately R2 of 0.99 for each well as per the manufacturer protocol.  Row A + H 
were not used as “background” rates for this assay due to inconsistency of the readings.  
The IC50 for each compound was calculated using the R statistical computing software 
with the package “drc” (R Core Team, 2014; Ritz et al., 2015).  The data was fit to a 
three-parameter logistic curve and the IC50 was defined as the concentration required to 
reach 50% inhibition of the activity of the DMSO control samples.  Data was visualized 
in R using the package “ggplot2”. 
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Computational Modeling 
GOLD docking software (v5.2.2) was utilized to perform molecular docking 
calculations for the AIMs using a crystal structure of Complex II from porcine heart with 
waters removed (PDB:1ZOY) (Jones et al. 1997; Sun et al. 2005).  The positions of the 
ubiquinone sites were determined using the related crystal structure of Complex II 
bound by the known inhibitors TTFA and 3-NP (PDB: 1ZP0).  The AIM compounds were 
docked in a 20 Å sphere centered on the hydroxy of residues Tyr-D91 & Tyr-D61 of the 
two ubiquinone sites (Qp and Qd, respectively).  The known inhibitor TTFA was also 
docked using the same method to validate the method. Docked poses were scored with 
the CHEMPLP scoring function and high-ranking poses were considered based on polar 
surface interaction distances and visualization by Pymol (Schrodinger 2015).  
Interaction diagrams were made using Discovery Studio (Dassault Systèmes, 2018). 
 
Determination of mtDNA Copy Number and Measurement of mtDNA Damage 
Cell Treatment & Sample Collection 
Treatment solutions were prepared in growth medium at various concentrations 
using a 5 mM compound stock solution prepared previously in sterile DMSO.  Medium 
was removed via aspiration and cells were rinsed with 2 mL of PBS.  The PBS was 
removed and medium containing the desired treatment was added to the culture dish.  
Cells were then incubated at growth conditions for the desired treatment period.  After 
treatment and incubation, medium was transferred to a 15 mL conical tube.  The cells 
were washed with 2 mL PBS and the wash was added to the 15 mL tube.  1.5 mL of 
trypsin-EDTA was added to the cells and they were incubated at 37° C for 
 121 
approximately 3 minutes to allow cells to detach.  Two mL of fresh growth medium was 
added to inactivate the trypsin-EDTA and the cells plus medium were transferred to the 
corresponding 15 mL tube.  Samples were centrifuged at 1,500 RPM for 5 minutes at 4° 
C, the supernatant was discarded, and pellets were resuspended in 1 mL PBS and 
transferred to 1.5 mL tubes.  The samples were then centrifuged at 5,000 RPM for 10 
minutes at 4 C.  The supernatants were discarded, and the pellets were frozen at -80° C 
until use. 
 
DNA Isolation 
Nuclear and mtDNA were isolated using a QIAGEN Blood & Cell Culture DNA 
Mini Kit as described in the protocol outlined by Chand and Chen (Chan and Chen 
2009).  Briefly, cells were thawed on ice and resuspended in 50 µL of nuclease-free 
water.  One mL of G2 digestion buffer was added to each tube and samples were 
vortexed immediately for 25 seconds.  Three µL of RNase A was added to each sample, 
mixed, and briefly centrifuged.  Twenty-five µL of reconstituted protease was added to 
each sample, and samples were inverted to mix.  Samples were then incubated in a 
water bath at 50° C for 1 hour.  Genomic tips were equilibrated for 15 minutes with QBT 
buffer and samples were vortexed 10 seconds and each transferred to a genomic tip 
following incubation.  Genomic tips were washed three times with 1 mL of QC buffer. 
Each DNA sample was eluted into a 15 mL tube by adding 910 µL of buffer QF, pre-
warmed to 50° C, twice to the corresponding genomic tip.  DNA was mixed by inversion 
and briefly centrifuged before dividing each sample into two 1.5 mL tubes. DNA was 
precipitated from each sample by addition of 700 µL of isopropanol, mixture by 
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inversion, and incubating at room temperature for 10 minutes.  Samples were 
centrifuged a 18,000 x g for 20 minutes at 4° C to pellet the nuclear and mitochondrial 
DNA.  The sample DNA pellets were washed twice with 500 µL ethanol pre-chilled to -
20° C, centrifuging at 18,000 x g for 10 minutes after each wash.  The supernatant was 
removed, and the residual ethanol was allowed to evaporate approximately 10 minutes 
in air.  Eighty µL TE buffer was added to each sample and the pellets were allowed to 
slowly dissolve overnight in the fridge at 4° C. 
 
DNA Quantification 
Sample DNA concentrations were measured using a NanoDrop instrument.  
Following initial measurements, dilutions were made at 10 ng/µL and measured again in 
triplicate.  Five ng/µL dilutions were made, measured in triplicate, and then diluted to 1 
ng/µL samples.  Five ng/µL samples were used for the nuclear marker in qPCR 
reactions.  One ng/µL samples were split equally, and one set was heated to 95° C for 6 
minutes in a PCR instrument to relax supercoiled mtDNA.  The 1 ng/µL samples, with 
and without heat treatment (native and relaxed), were then used for the mtDNA markers 
in qPCR reactions. 
 
Standards Preparation 
Standards were prepared using DNA isolated from untreated SNB-19 cells.  For 
both mtDNA markers (D-loop & CO-2), standards were prepared by PCR using DNA 
isolated from untreated SNB-19 cells.  Fifty µL PCR reactions were performed to amplify 
a 3285 b.p. fragment (CO-2) and a 2467 b.p. fragment (D-loop).  Each reaction 
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contained 5 µL of 10x Thermophilus DNA polymerase buffer (Fisher Scientific), 4 µL of 
25 mM MgCl2, 1 µL of 10 mM dNTP mixed bases, 0.5 µL of Tth DNA polymerase 
(Fisher Scientific), 0.4 µL of both the respective upstream and downstream primers, 17 
µL of DNA stock at 0.031 µg / µL, and 21.9 µL of ddH2O.  Reactions were carried out in 
a thermocycler using the following settings:  94° C for 2 minutes, followed by 30 cycles 
of 94° C for 15 seconds, 60° C for 30 seconds, and 72° C for 3 minutes 30 seconds.  
Samples were then left at 72° C for 5 minutes prior to holding at 10° C at the end of the 
reaction.  Reaction products were purified using the Qiagen “Qiaquick (50)” kit as per 
manufacturer instructions.  The mtDNA (D-loop & CO-2) standards were then serially 
diluted to form standards from 3,000,000 to 30 copies.  Primers used for the reactions 
are outlined in the protocol from Chan et al., 2012.  For Calicin nuclear DNA standards, 
DNA isolated from SNB-19 control cells was serially 5-fold diluted from 40 ng / µL to 
0.064 ng / µL to create the 5 nuclear standards used. 
 
qPCR for Measurement of mtDNA Copy Number and Damage 
Changes in mtDNA damage and copy number were measured using a protocol 
previously published method (Chan et al. 2012).  Samples and standards were gently 
mixed by flicking and centrifuged briefly.  PCR mastermixes were prepared for each 
marker (Calicin, CO-2, and d-loop) using stock solutions of the appropriate forward and 
reverse primers along with nuclease free water and SYBR Mix.  Each reaction volume 
was set at 20 µL and contained 0.7 µL of the forward and reverse primers, 7.6 µL of 
nuclease-free water and 10 µL of SYBR mix along with 1 µL of template DNA.  The 
primers used for these reactions are outlined in the protocol from Chan, 2012.  The 
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qPCR reactions were carried out on a Stratagene qPCR instrument using the following 
settings:  95° C for 30 seconds, followed by 40 cycles of 95° C for 3 seconds and 60° C 
for 30 seconds.  Following completion of the 40 cycles, a dissociation melting curve was 
created for each sample by heating to 95° C 30 seconds, cooling 55° C for 30 seconds, 
and finally heating to 95° C for 30 seconds. 
 
Data Analysis 
Six-point standard curves from 3e6 copies to 3e1 copies were created for the 
mtDNA markers (CO-2 & D-loop) using the qPCR standards reactions.  This was used 
to quantify the precise copy number of the mtDNA markers in each of the control and 
treatment samples.  For the nuclear marker (Calicin), a standard curve was constructed 
using the 5 standard samples ranging from 40 ng / µL to 0.064 ng / µL.  Calicin is a 
single copy nuclear gene, and with this in mind the following equation was used to 
calculate the approximate number of cells in each standard sample:  
(𝐴𝑝𝑝𝑟𝑜𝑥.		𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝐶𝑒𝑙𝑙𝑠) = 	
[𝑆𝑎𝑚𝑝𝑙𝑒𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛] × (6.022 × 10fg)
(3088286401) × (660) × (1 × 10k) ×
1
2 
Where 6.022 x 1023 is Avogadro’s constant used to convert to moles, 3,088,286,401 are 
the number of base pairs in the human genome, 660 g/mol/bp is the average molecular 
weight of a DNA base pair, 1 x 109 is a conversion factor (g to ng) and 1/2 to account for 
a diploid genome.  The approximate number of cells in each qPCR control or treated 
sample was then calculated using the Calicin standard curve and normalized to 5 ng/µL 
using the concentration measured previously by NanoDrop.  The percent of damage in 
each sample for both mtDNA markers (CO-2 & D-loop) was determined as outlined by 
Chen and Chan (Number of Copies in Unheated Sample / Number of Copies in related 
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Pre-heated sample) (Chan and Chen 2009).  Statistical analysis was performed by 
ANOVA with Dunnett’s post-hoc tests using the R statistical computing software and the 
library “DescTools” (R Core Team, 2014; Signorell, 2019). 
 
Annexin-V / Propidium Iodide Flow Cytometry 
Apoptosis was assessed using a commercially available Annexin-V / Propidium 
Iodide kit according to the manufacturer protocol (BD Biosciences FITC Annexin V 
Apoptosis Detection Kit I #556547).  SNB-19 human glioblastoma cells were cultured at 
optimal growth conditions.  Cells were seeded at a density of 250,000 cells / mL in 
sterile 6-well polystyrene plates (35mm / well) and let adhere overnight at growth 
conditions.  Medium was removed by aspiration and cells were treated with medium 
containing either DMSO vehicle or AIMs at the desired concentration and incubated at 
optimal growth conditions for 24 hours.  Following incubation, culture medium from each 
sample was collected in 15 mL tubes and cells were rinsed with 2 mL PBS prior to 
adding 2 mL Trypsin-EDTA to each well.  Cells were again incubated at growth 
conditions for 5 minutes to detach adherent cells prior to adding 2 mL of fresh medium.  
The PBS rinse and medium containing unadhered cells, was combined with the medium 
contained in the corresponding 15 mL tube.  Samples were centrifuged at 3,000 RPM 
for 5 minutes at 4 C° to pellet the cells.  The supernatant from each sample was 
discarded and pellets were each resuspended in 1 mL PBS prior to transfer to 1.5 mL 
tubes.   Cells were counted using a Beckman Coulter® automated cell counter prior to a 
second centrifugation at 3,000 RPM for 5 minutes.  Sample supernatants were then 
discarded and cells were resuspended in Binding Buffer at approximately 1 million cells 
 126 
/ mL.  Approximately 200 µL of each sample was transferred to a new 1.5 mL tube and 
5 µL of FITC Annexin-V dye was added to each sample prior to incubation for 15 
minutes at room temperature.  Following incubation, 300 uL of binding buffer was added 
to each sample before transfer to a 12x75mm culture tube through a 35 µm cell strainer 
cap.  Samples were kept on ice and 1 µL of propidium iodide was added immediately 
prior to analysis on a Attune NxT flow cytometer.  Data analysis was performed using 
the FlowJo v10.5.2 software.  Statistical analysis was performed by ANOVA with 
Dunnett’s post-hoc tests using the R statistical computing software and the library 
“DescTools” (R Core Team, 2014; Signorell, 2019). 
 
JC-1 Flow Cytometry 
Mitochondrial membrane potential (ΔΨm) was analyzed using a commercially 
available JC-1 assay kit according to the manufacturer protocol (Thermo Fisher 
MitoProbe™ JC-1 Assay Kit for Flow Cytometry #M34152).  SNB-19 human 
glioblastoma cells were cultured at optimal growth conditions.  Cells were seeded at a 
density of 250,000 cells / mL in sterile 6-well polystyrene plates (35mm / well) and let 
adhere overnight at growth conditions.  Medium was removed by aspiration and cells 
were treated with medium containing either DMSO vehicle or AIMs at the desired 
concentration and incubated at 37 C° in 5% CO2 for 24 hours.  Following incubation, 
culture medium from each sample was collected in 15 mL tubes and cells were rinsed 
with 2 mL PBS prior to adding 2 mL Trypsin-EDTA to each well.  Cells were again 
incubated at 37 C° in 5% CO2 for 5 minutes to detach adherent cells prior to adding 2 
mL of fresh medium.  The PBS rinse and medium containing unadhered cells, was 
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combined with the medium contained in the corresponding 15 mL tube.  Samples were 
centrifuged at 3,000 RPM for 5 minutes at 4 C° to pellet the cells.  The supernatant from 
each sample was discarded and pellets were each resuspended in 1 mL PBS prior to 
transfer to 1.5 mL tubes.   Cells were counted using a Beckman Coulter® automated 
cell counter prior to a second centrifugation at 3,000 RPM for 5 minutes.  Sample 
supernatants were then discarded and cells were resuspended in 1 mL PBS at 
approximately 1 million cells / mL and allowed to equilibrate to room temperature.  To 
each sample, 10 µL of JC-1 dye was added prior to incubation for 30 minutes at 37 C° 
in 5% CO2.  Following incubation, cells were pelleted by centrifugation at 3,000 RPM for 
5 minutes at 4 C°.  Sample pellets were resuspended in 500 µL of PBS before transfer 
to a 12x75mm culture tube through a 35 µm cell strainer cap.  Samples were kept on ice 
until analysis on a Attune NxT flow cytometer.  Data analysis was performed using the 
FlowJo v10.5.2 software.  Statistical analysis was performed by ANOVA with Dunnett’s 
post-hoc tests using the R statistical computing software and the library “DescTools” (R 
Core Team, 2014; Signorell, 2019). 
 
Caspase-9 Flow Cytometry 
Caspase-9 activity was determined using a commercially available kit according 
to the manufacturer protocol (SR-FLICA® Caspase-9 Assay Kit (#961)).  SNB-19 
human glioblastoma cells were cultured at optimal growth conditions.  Cells were 
seeded at a density of 250,000 cells / mL in sterile 6-well polystyrene plates (35mm / 
well) and let adhere overnight at growth conditions.  Medium was removed by aspiration 
and cells were treated with medium containing either DMSO vehicle or AIMs at the 
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desired concentration and incubated at 37 C° in 5% CO2 for 24 hours.  Following 
incubation, culture medium from each sample was collected in 15 mL tubes and cells 
were rinsed with 2 mL PBS prior to adding 2 mL Trypsin-EDTA to each well.  Cells were 
again incubated at 37 C° in 5% CO2 for 5 minutes to detach adherent cells prior to 
adding 2 mL of fresh medium.  The PBS rinse and medium containing unadhered cells, 
was combined with the medium contained in the corresponding 15 mL tube.  Samples 
were centrifuged at 3,000 RPM for 5 minutes at 4 C° to pellet the cells.  The 
supernatant from each sample was discarded and pellets were each resuspended in 1 
mL PBS prior to transfer to 1.5 mL tubes.   Cells were counted using a Beckman 
Coulter® automated cell counter prior to a second centrifugation at 3,000 RPM for 5 
minutes.  Samples were resuspended in 500 µL of medium and 16.7 µL of the SR-
FLICA reagent was added (1:30) prior to incubation for 1 hour at 37 C° in 5% CO2 with 
brief mixing every 10 minutes.  Samples were then centrifuged at 3,000 RPM for 5 
minutes and, after removal of the supernatant, pellets were resuspended in 500 µL 
apoptosis wash buffer and incubated at 37 C° in 5% CO2 for 10 minutes to allow 
unbound SR-FLICA reagent to diffuse out of the cells.  The wash step was repeated two 
additional times prior to resuspension in 500 µL of fresh apoptosis wash buffer and 
transfer to a 12x75mm culture tube through a 35 µm cell strainer cap.  Samples were 
kept on ice and immediately analyzed on a Attune NxT flow cytometer.  Data analysis 
was performed using the FlowJo v10.5.2 software.  Statistical analysis was performed 
by ANOVA with Dunnett’s post-hoc tests using the R statistical computing software and 
the library “DescTools” (R Core Team, 2014; Signorell, 2019). 
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Caspase-3/7 Flow Cytometry 
Caspase-3/7 activity was determined using a commercially available kit 
according to the manufacturer protocol (SR-FLICA® Caspase-3/7 Assay Kit (#931)).  
SNB-19 human glioblastoma cells were cultured at optimal growth conditions.  Cells 
were seeded at a density of 250,000 cells / mL in sterile 6-well polystyrene plates 
(35mm / well) and let adhere overnight at growth conditions.  Medium was removed by 
aspiration and cells were treated with medium containing either DMSO vehicle or AIMs 
at the desired concentration and incubated at 37 C° in 5% CO2 for 24 hours.  Following 
incubation, culture medium from each sample was collected in 15 mL tubes and cells 
were rinsed with 2 mL PBS prior to adding 2 mL Trypsin-EDTA to each well.  Cells were 
again incubated at 37 C° in 5% CO2 for 5 minutes to detach adherent cells prior to 
adding 2 mL of fresh medium.  The PBS rinse and medium containing unadhered cells, 
was combined with the medium contained in the corresponding 15 mL tube.  Samples 
were centrifuged at 3,000 RPM for 5 minutes at 4 C° to pellet the cells.  The 
supernatant from each sample was discarded and pellets were each resuspended in 1 
mL PBS prior to transfer to 1.5 mL tubes.   Cells were counted using a Beckman 
Coulter® automated cell counter prior to a second centrifugation at 3,000 RPM for 5 
minutes.  Samples were resuspended in 500 µL of medium and 16.7 µL of the SR-
FLICA reagent was added (1:30) prior to incubation for 1 hour at 37 C° in 5% CO2 with 
brief mixing every 10 minutes.  Samples were then centrifuged at 3,000 RPM for 5 
minutes and, after removal of the supernatant, pellets were resuspended in 500 µL 
apoptosis wash buffer and incubated at 37 C° in 5% CO2 for 10 minutes to allow 
unbound SR-FLICA reagent to diffuse out of the cells.  The wash step was repeated two 
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additional times prior to resuspension in 500 µL of fresh apoptosis wash buffer and 
transfer to a 12x75mm culture tube through a 35 µm cell strainer cap.  Samples were 
kept on ice and immediately analyzed on a Attune NxT flow cytometer.  Data analysis 
was performed using the FlowJo v10.5.2 software.  Statistical analysis was performed 
by ANOVA with Dunnett’s post-hoc tests using the R statistical computing software and 
the library “DescTools” (R Core Team, 2014; Signorell, 2019). 
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Results 
AIMs Reduce Cell Viability in Tumor Cells 
MTT Cell Viability Assay 
 We utilized an MTT assay to determine the effect of the 10-Phenyl and 10-
Biphenoxy AIMs on cell viability.  The 10-Phenyl and the 10-Biphenoxy AIMs both 
demonstrated sub-micromolar toxicity in the SNB-19 human glioblastoma cells (Table 
3.7).  The 10-Biphenoxy AIM was the most effective at inhibiting the growth of SNB-19 
cells, with a calculated IC50 of 0.68 ± 0.04 µM (Figure 3.2).  The 10-Phenyl AIM showed 
similar toxicity of 0.89 ± 0.02 µM in the cells. 
 
Table 3.7 Cell viability results from MTT assay 
SNB-19 
(Human Glioblastoma) 
Compound IC50 (µM) 95% CI (±) 
10-Phenyl AIM 0.89* 0.02* 
10-Biphenoxy AIM 0.68 0.04 
*Previously published in BMCL, error for these values is ±Standard Deviation (Weaver et al. 2015) 
AIMs cause loss of cell viability in SNB-19 human glioblastoma cells at sub-micromolar 
concentrations following 24-hour treatment.  Results shown are the average of three 
MTT experiments each.  IC50 is defined as the concentration required to inhibit the 
growth of 50% of the cells. 
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Figure 3.2 Example dose-response curve for MTT assay in SNB-19 cells 
Example of SNB-19 dose-response curve generated using the MTT cell viability assay 
as described.  Error bars represent standard deviations, IC50 shown as a vertical black 
line with dotted lines representing the respective 95% confidence interval. 
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LDH Cell Viability Assay 
 As a separate measure of cell viability not dependent on mitochondrial reductase 
function, we employed an LDH assay to measure the effect of the AIMs in multiple cell 
types (SNB-19, C6, and E-18).  The AIMs demonstrated low-micromolar toxicity in all of 
the cells tested (Table 3.8).  The 10-Biphenoxy remained the most potent compound 
tested in the SNB-19 human glioblastoma cells with an IC50 of 4.44±0.16 µM (Figure 
3.3).  The 10-Biphenoxy and 10-Phenyl had comparable activity in the C6 rat glioma 
cells (C6 IC50 = 3.83±0.10 µM and 3.76±0.12 µM, respectively) (Figure 3.4).  
Surprisingly, the 10-Biphenoxy and 10-Phenyl AIMs showed more toxicity toward the 
primary E-18 healthy rat astrocytes than the C6 rat glioma cells (E-18 IC50 = 2.09±0.20 
µM and 2.20±0.16 µM, respectively) (Figure 3.5). 
 
Table 3.8 Cell viability results from LDH assay 
SNB-19 
(Human Glioblastoma) 
 
C6 
(Rat Glioma) 
 
E-18 
(Primary Rat Astrocytes) 
Compound 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
10-Phenyl AIM 
 
5.92 0.68 
 
3.76 0.12 
 
2.20 0.16 
10-Biphenoxy AIM 
 
4.44 0.16 
 
3.83 0.10 
 
2.09 0.20 
AIMs reduce cell viability in SNB-19 human glioblastoma cells at low-micromolar 
concentrations following 24-hour treatment.  Results shown are the average of three 
LDH experiments each.  IC50 is defined as the concentration required to inhibit the 
growth of 50% of the cells. 
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Figure 3.3 Example dose-response curve for LDH assay in SNB-19 cells 
Example of SNB-19 dose-response curve generated using the LDH cytotoxicity assay 
as described.  Error bars represent standard deviations, IC50 shown as a vertical black 
line with dotted lines representing the respective 95% confidence interval. 
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Figure 3.4 Example dose-response curve for LDH assay in C6 cells 
Example of C6 dose-response curve generated using the LDH cytotoxicity assay as 
described.  Error bars represent standard deviations, IC50 shown as a vertical black line 
with dotted lines representing the respective 95% confidence interval. 
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Figure 3.5 Example dose-response curve for LDH assay in E-18 cells 
Example of E-18 dose-response curve generated using the LDH cytotoxicity assay as 
described.  Error bars represent standard deviations, IC50 shown as a vertical black line 
with dotted lines representing the respective 95% confidence interval. 
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AIMs Localize to the Mitochondria of Glioblastoma Cells 
Confocal Imaging 
 We performed confocal imaging of SNB-19 glioblastoma cells to examine the 
intracellular localization of the AIMs.  The AIMs are conveniently auto-fluorescent and 
can be visualized in cells using laser excitation.  The MitoTracker™ dye selectively 
stains the mitochondria of living cells.  Treatment with 1 µM of the 10-Phenyl AIM and 
100 nM MitoTracker™ demonstrates localization of the AIMs to the mitochondria of 
glioblastoma cells (Figure 3.6).  This was also shown for the 10-Biphenoxy AIM under 
the same conditions (Figure 3.7).  Confocal Z-stacks further verified the mitochondrial 
localization of the AIMs in the glioblastoma cells (Figure 3.8 and Figure 3.9).  However, 
it is noted that it appears the AIMs may also be present in other organelles or vesicles 
as well.  Taken together, these results confirm both the 10-Phenyl and 10-Biphenoxy 
AIMs can localize to the mitochondria of glioblastoma cells. 
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10-Phenyl AIM Mitotracker Overlay 
   
Figure 3.6 Confocal images of SNB-19 cells with 10-Phenyl AIM 
Confocal images of SNB-19 human glioblastoma cells treated with 1 µM of the 10-
Phenyl AIM (green, left), 100 nM Mitotracker (magenta, middle), and overlay (white, 
right).  Scale bar shown is 20 µM. 
 
10-Biphenoxy AIM Mitotracker Overlay 
   
Figure 3.7 Confocal images of SNB-19 cells with 10-Biphenoxy AIM 
Confocal images of SNB-19 human glioblastoma cells treated with 1 µM of the 10-
Biphenoxy AIM (green, left), 100 nM Mitotracker (magenta, middle), and overlay (white, 
right).  Scale bar shown is 20 µM. 
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Figure 3.8 Confocal Z-stack images of SNB-19 cells with 10-Phenyl AIM 
Confocal Z-stack images of SNB-19 human glioblastoma cells treated with 500 nM of 
the 10-Phenyl AIM and 100 nM Mitotracker with co-localization observed as white.  
Scale bar shown is 20 µM.  Images shown represent 4 µm of total depth and each 
individual image is separated by 1 µm depth. 
 
 140 
 
Figure 3.9 Confocal Z-stack images of SNB-19 cells with 10-Biphenoxy AIM 
Confocal Z-stack images of SNB-19 human glioblastoma cells treated with 500 nM of 
the 10-Biphenoxy AIM and 100 nM Mitotracker with co-localization observed as white.  
Scale bar shown is 20 µM.  Images shown represent 9 µm of total depth and each 
individual image is separated by 1.5 µm depth. 
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AIMs Inhibit Mitochondria ETC Complexes 
We measured the inhibitory effect of the AIMs on Complex I – IV of the ETC 
using commercially available kits (Table 3.9).  The AIMs were measured using the 
antibody isolated ETC complexes for Complex I, II, and IV.  For Complex II + III, the 
assay utilized intact mitochondria, but cannot distinguish between the two ETC protein 
complexes. 
The AIM compounds tested do not appear to be significant inhibitors of Complex 
I.  However, both the 10-Phenyl and 10-Biphenoxy showed significant inhibition in the 
Complex II assay (IC50 = 18.3 ± 10.7 µM and 2.9 ± 1.2 µM, respectively) (Figure 3.10 
and Figure 3.11).  The Complex II + III assay in intact mitochondria showed inhibition of 
25.63 ± 3.78 µM for the 10-Phenyl AIM and 8.67 ± 0.68 for the 10-Biphenoxy AIM 
(Figure 3.12 and Figure 3.13). 
There was also some inhibition observed for Complex IV for the 10-Biphenoxy 
AIM with a calculated IC50 of 26.89 ± 2.87 µM, however even at 90 µM the 10-Phenyl 
did not reach 50% inhibition (Appendix Figure A.3.10 and Figure A.3.11). 
   
Table 3.9 Summary of ETC protein complex assay results 
IC50 (µM ± 95%CI)  10-Phenyl AIM 10-Biphenoxy AIM Rotenone Antimycin A 
Complex I > 90 > 90 0.121 ± 0.031 
 
Complex II 18.27 ± 10.72 2.91 ± 1.21 
  
Complex II + III* 25.63 ± 3.78 8.67 ± 0.68 
 
0.059 ± 0.008 
Complex IV > 90 26.89 ± 2.87 
  
*Intact Bovine Heart Mitochondria 
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Figure 3.10 Complex II inhibition curve for the 10-Phenyl AIM 
Complex II inhibition curve for the 10-Phenyl AIM.  Points represent individual 
measurements, curve represents three-parameter logistic fit with shaded area indicating 
the 95% confidence interval of the fit. (n=3) 
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Figure 3.11 Complex II inhibition curve for the 10-Biphenoxy AIM 
Complex II inhibition curve for the 10-Biphenoxy AIM.  Points represent individual 
measurements, curve represents three-parameter logistic fit with shaded area indicating 
the 95% confidence interval of the fit. (n=3) 
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Figure 3.12 Complex II + III inhibition curve for the 10-Phenyl AIM 
Complex II + III inhibition curve for the 10-Phenyl AIM in intact mitochondria.  Points 
represent individual measurements, curve represents three-parameter logistic fit with 
shaded area indicating the 95% confidence interval of the fit. (n=3) 
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Figure 3.13 Complex II + III inhibition curve for the 10-Biphenoxy AIM 
Complex II + III inhibition curve for the 10-Biphenoxy AIM in intact mitochondria.  Points 
represent individual measurements, curve represents three-parameter logistic fit with 
shaded area indicating the 95% confidence interval of the fit. (n=3)  
0
25
50
75
100
0.01 0.10 1.00 10.00 90.00
Concentration (uM)
%
 A
ct
iv
ity
Complex II + III Inhibition 
 Treatment: 10'Biphenoxy AIM
 146 
Computational Modeling 
The authors would like to acknowledge Michael J. Campbell of the Natale 
Laboratory, and the Molecular Computational Core Facility (MCCF) at the University of 
Montana for their contributions to these experiments. 
 To further examine the interaction of the AIMs with Complex II, we performed 
molecular docking studies at the ubiquinone sites of a crystal structure of the protein 
complex (PDB: 1ZOY) (Sun et al. 2005).  We chose the ubiquinone sites as the 
succinate site was determined to be too inaccessible for binding by AIMs.  First, we 
verified the known Complex II inhibitor TTFA was docked correctly by GOLD in both 
ubiquinone sites (Qp and Qd) in comparison to a crystal structure of a Complex II / TTFA 
complex (PDB: 1ZP0) (Figure 3.14).  Next, we performed molecular docking 
calculations for both the 10-Phenyl and 10-Biphenoxy AIMs and evaluated the top 10 
docking poses determined by their CHEMPLP fitness scores (Table 3.10 and Table 
3.11).  The top pose for the 10-Biphenoxy AIM show the biphenyl moiety in the 
ubiquinone binding pocket of the Qp site, with the anthracene in proximity to allow for p-
p interactions with the Trp-B173 and His-C29 (Figure 3.15 and Figure 3.16).  There are 
also carbon hydrogen bond interactions suggested at Tyr-91 and Val-81 by the alkyl 
amine tails.  Finally, the biphenyl moiety interacts with Trp-B173, Met-C39, Pro-B169 
and Ile-C43.  The top pose for the 10-Phenyl AIM suggests the smaller phenyl moiety 
allows for deeper access in the binding pocket for the anthracene portion of the 
molecule and displays p-p interactions with Pro-B169 and Ile-C43.   The phenyl moiety 
shows p-p interactions with Ile-B218 and Arg-C46, and other parts of the AIM molecule 
suggest various other potential interactions (Figure 3.17 and Figure 3.18). 
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Table 3.10 Docking scores for Complex II Qp site 
Complex II Qp Site GOLD Docking Results 
Solution # CHEMPLP Fitness Score 
 10-Phenyl 10-Biphenoxy TTFA 
1 82.78 75.21 48.51 
2 101.67 51.74 50.37 
3 80.76 66.21 49.56 
4 88.81 61.43  
5 78.59 78.05  
6 79.22 75.02  
7 92.00 82.75  
8 81.84 80.25  
9 78.14 66.68  
10 83.73 88.45  
 
Docking scores calculated for TTFA and the 10-Phenyl and 10-Biphenoxy AIMs at the 
Qp ubiquinone site of a crystal structure of Complex II (PDB: 1ZOY). 
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Table 3.11 Docking scores for Complex II Qd site 
Complex II Qd Site GOLD Docking Results 
Solution # CHEMPLP Fitness Score 
 10-Phenyl 10-Biphenoxy TTFA 
1 86.54 78.32 44.38 
2 79.88 74.56 43.35 
3 88.98 80.46 43.91 
4 85.29 69.66 44.45 
5 84.56 85.98 44.10 
6 90.12 71.36  
7 86.37 70.63  
8 86.97 70.82  
9 90.20 78.60  
10 84.65 71.38  
 
Docking scores calculated for TTFA and the 10-Phenyl and 10-Biphenoxy AIMs at the 
Qd ubiquinone site of a crystal structure of Complex II (PDB: 1ZOY). 
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Figure 3.14 Complex II computational docking with TTFA 
Overlay of TTFA from a published crystal structure (PDB: 1ZP0, magenta) with the 
highest scoring TTFA pose from GOLD (green) in the Qp ubiquinone site of the crystal 
structure of Complex II (PDB: 1ZOY). 
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Figure 3.15 Complex II computational docking with 10-Biphenoxy AIM 
Overlay of the three top scoring poses for the 10-Biphenoxy AIM from GOLD in the Qp 
ubiquinone site. Solutions 5, 7 and 10 shown as green, magenta and yellow, 
respectively.  View is the same orientation as Figure 3.14. 
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Figure 3.16 Diagram of ligand interactions for 10-Biphenoxy AIM 
2D diagram showing ligand interactions for the top scoring pose for the 10-Biphenoxy 
AIM from GOLD in the Qp ubiquinone site (Solution #10).  Interaction distances are 
labeled in angstrom units. 
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Figure 3.17 Complex II computational docking with 10-Phenyl AIM 
Overlay of the three top scoring poses for the 10-Phenyl AIM from GOLD in the Qp 
ubiquinone site. Solutions 2, 7 and 10 shown as green, magenta and yellow, 
respectively.  View is the same orientation as Figure 3.14. 
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Figure 3.18 Diagram of ligand interactions for 10-Phenyl AIM 
2D diagram showing ligand interactions for the top scoring pose for the 10-Phenyl AIM 
from GOLD in the Qp ubiquinone site (Solution #2).  Interaction distances are labeled in 
angstrom units.  
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Treatment with AIMs leads to rapid mtDNA damage and reduced mtDNA copy 
number in glioblastoma cells 
 To measure the effect of treatment with the 10-Biphenoxy AIM on mtDNA, we 
employed a previously reported method to examine changes in mtDNA damage and 
copy number (Chan and Chen 2009; Chan et al. 2012).  A time-course was performed 
to determine the effect of 10-Biphenoxy AIM treatment at multiple exposure time points 
(3, 6, 12, and 24 hours).  Treatment with 1 µM of the 10-Biphenoxy AIM caused a 
significant increase in percentage damaged mtDNA the CO-2 gene (Figure 3.19).  A 
reduction in the number of intact copies, normalized to a single-copy nuclear gene 
Calicin, was significant at the 6-hour time-point for both the CO-2 and D-loop mtDNA 
markers (Figure 3.20).  Further examination of the intact copy number per cell led us to 
determine the variance in the 24-hour group was a significant outlier in both markers as 
calculated by a Cochran’s C test in R using the “outliers” package (P = 0.03 and P = 
0.002 for D-loop and CO-2 genes, respectively) (R Core Team, 2014, Komsta, 2011).  
As a result, we excluded the 24-hour group and reanalyzed the time-course experiment 
data.  This allowed us to demonstrate a significant change in the number of intact 
copies per cell for the CO-2 gene at the 3-, 6-, and 12-hour time-points, and for the D-
loop gene at 6- and 12-hours following treatment with the 10-Biphenoxy AIM (Figure 
3.21). 
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Figure 3.19 mtDNA damage following treatment with 10-Biphenoxy AIM 
Treatment with 1 µM 10-Biphenoxy AIM causes a significant increase in the percent 
damage in CO-2 gene of mtDNA at 3 hours and 6 hours.  Error bars represent standard 
deviation.  Dunnett post-hoc test used for comparisons between treatment and control 
groups.  Symbols represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) 
(n=3). 
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Figure 3.20 Intact copy number of mtDNA following treatment with 10-Biphenoxy AIM 
Treatment with 1 µM 10-Biphenoxy AIM causes a decrease in the intact copies per cell 
of two mtDNA markers (CO-2 & D-loop) after 6 hours.  Error bars represent standard 
deviation.  Dunnett post-hoc test used for comparisons between treatment and control 
groups.  Symbols represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) 
(n=3). 
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Figure 3.21 Intact copy number of mtDNA following treatment with 10-Biphenoxy AIM 
Treatment with 1 µM 10-Biphenoxy AIM causes a decrease in the intact copies per cell 
of two mtDNA markers (CO-2 & D-loop) at multiple time points.  Same as previous 
figure except with 24-hour group excluded from analysis due to significantly higher 
variance in the group as determined by Cochran’s C test (P = 0.03 and P = 0.002 for D-
loop and CO-2 genes, respectively).  Error bars represent standard deviation.  Dunnett 
post-hoc test used for comparisons between treatment and control groups.  Symbols 
represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) (n=3). 
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AIMs Induce Apoptosis in Glioblastoma Cells 
 Apoptosis was measured in SNB-19 human glioblastoma cells following 
treatment with the AIMs using flow cytometry in conjunction with Annexin-V and 
propidium iodide staining.  The Annexin-V / PI results confirmed induction of apoptosis 
in SNB-19 glioblastoma cells by the 10-Biphenoxy AIM (Figure 3.22).  Statistical 
analysis performed for the 10-Biphenoxy AIM showed a significant decrease in the 
healthy cell population for the 2.5 µM and 5 µM treatments (Figure 3.23).  The 5 µM 10-
Biphenoxy AIM treated samples showed a significant increase in apoptosis with a mean 
of 92.8% of the total cell population versus only 3.9% observed in the control samples.  
There was also a significant decrease observed in the amount of necrosis in the 5 µM 
treatment versus control samples.  These results suggest the AIMs are potent activators 
of apoptosis in glioblastoma cells without causing an increase in necrosis. 
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Figure 3.22 Dot-plots of the flow cytometry experiments with Annexin-V/PI 
Representative dot-plots of the flow cytometry experiments with Annexin-V and 
propidium iodide staining.  Quadrants are defined as follows: Q1 is necrosis, Q2 is late 
apoptosis, Q3 is early apoptosis, and Q4 is healthy non-apoptotic cells. 
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Figure 3.23 Statistical analysis of the flow cytometry experiments with Annexin-V/PI 
Treatment with 5 µM of 10-Biphenoxy AIM for 24-hours causes a significant increase in 
early apoptosis (P = 0.0001).  A significant decrease in the population of healthy cells 
relative to control is observed for both the 2.5 µM and 5 µM 10-Biphenoxy AIM treated 
groups (P = 0.009 and P = 2E-16, respectively).  No increase in necrosis is observed for 
any 10-Biphenoxy treatment group.  Healthy ANOVA P = 1.58E-14.  Early Apoptosis 
ANOVA P = 1.21E-13.  Late Apoptosis ANOVA P = 1.11E-4.  Necrosis ANOVA P = 
0.04. Symbols represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) 
(n=3). 
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Treatment with AIMs Induces Loss of Mitochondrial Membrane Potential 
 To determine the effect of the 10-Biphenoxy AIM on the mitochondrial membrane 
potential, the mitochondrial dye JC-1 was utilized.  JC-1 accumulates in mitochondria 
with a normal mitochondrial membrane potential (ΔΨm) and the aggregates formed 
fluoresces red, however when there is a loss of the ΔΨm, the dye leaks into the cytosol 
where it becomes monomers which fluoresce green. 
In analysis of the JC-1 data utilizing only the 488 nm excitation wavelength, the 5 
µM 10-Biphenoxy AIM treated cells revealed a dramatic shift to 88.0% of cells 
demonstrating mitochondrial depolarization, as indicated by the green fluorescence of 
JC-1 monomers (Figure 3.24 and Figure 3.25).  This is in stark contrast to only 6.4% of 
cells showing mitochondrial depolarization in the control samples.  The positive control 
behaved as expected and the 50 µM CCCP treated group showed approximately 75.1% 
of the cells with depolarized mitochondria. 
Consideration of the data collected using the alternative excitation wavelength of 
405 nm to better distinguish JC-1 aggregates, we show that the increase in 
mitochondrial hyperpolarization, as defined by an increase in red fluorescence, was 
statistically significant for the 1 µM and 2.5 µM 10-Biphenoxy AIM treatment groups 
(Figure 3.26 and Figure 3.27).  The 5 µM 10-Biphenoxy AIM treatment group did not 
show a significant increase in hyperpolarization, however did show significant increases 
in partial and full depolarization populations as they were defined by our gating strategy, 
and this is similar to that observed for the 50 µM CCCP positive control group.  As a 
result, the percentage of cells displaying normal mitochondrial polarization showed a 
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dose-dependent decrease with increasing concentrations of 10-Biphenoxy AIM 
treatment. 
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Figure 3.24 Dot-plots of the flow cytometry experiments with JC-1 at 488 nm 
Representative dot-plots of the flow cytometry experiments with JC-1 staining and 488 
nm excitation.  Gated area is defined as JC-1 monomers indicated by a decrease in red 
fluorescence (529 nm) and increase in green fluorescence (590 nm). 
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Figure 3.25 Analysis of mitochondrial membrane potential using JC-1 at 488 nm 
24-hour treatment with 5 µM 10-Biphenoxy AIM causes a decrease in mitochondrial 
membrane potential observed as a significant increase of JC-1 monomers in SNB-19 
human glioblastoma cells (P = <2E-16).  50 µM CCCP used as a positive control (P = < 
2E-16).  ANOVA P = 6.18E-12.  Error bars represent standard deviation.  Dunnett post-
hoc test used for comparisons between treatment and control groups.  Symbols 
represent significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) (n=3). 
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Figure 3.26 Analysis of mitochondrial membrane potential using JC-1 at 405/488 nm 
Representative dot-plots of the flow cytometry experiments with JC-1 staining and 
excitation at 405 nm and 488 nm.  Quadrants are defined as follows: Q1 is 
hyperpolarized (­ red fluorescence), Q2 is partially depolarized (­ green & ­ red 
fluorescence), Q3 depolarized (­ green fluorescence), and Q4 is normal (control level 
red and green fluorescence).    
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Figure 3.27 Analysis of mitochondrial membrane potential using JC-1 at 405/488 nm 
24-hour treatment with 10-Biphenoxy AIM at increasing concentrations effects the 
mitochondrial membrane potential in SNB-19 human glioblastoma cells.  50 µM CCCP 
used as a positive control.  Hyperpolarized (ΔΨm) ANOVA P = 0.0005.  Depolarized 
(ΔΨm) ANOVA P = 1.14E-05.  Partial Depolarization (ΔΨm) ANOVA P = 0.001.  Normal 
(ΔΨm) ANOVA P = 0.007.  Error bars represent standard deviation.  Dunnett post-hoc 
test used for comparisons between treatment and control groups.  Symbols represent 
significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***). 
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AIMs Induce the Mitochondrial-mediated Intrinsic Pathway of Apoptosis 
To measure activation of the intrinsic pathway of apoptosis, we performed flow 
cytometry experiments with SR-LEHD-FMK and SR-DEVD-FMK staining to detect 
activity of caspases 9 and 3/7, respectively.  Caspase-9 is an initiator caspase and is 
involved in formation of the apoptosome that is responsible for cleavage of executioner 
pro-caspases-3 and 7 to their active forms.  These data showed a significant 1.7-fold 
increase in caspase-9 staining in the 5 µM 10-Biphenoxy AIM treatment group in SNB-
19 glioblastoma cells (Figure 3.28 and Figure 3.29).  Importantly, the increase in 
caspase-9 staining corresponded to a significant increase in caspase-3/7 staining 
(Figure 3.30 and Figure 3.31).  The increase in caspase-3/7 was approximately 1.9-
fold in the 5 µM 10-Biphenoxy AIM treatment group, similar to that observed for 
caspase-9.  The amount of caspase-3/7 staining appeared higher in the cells than 
caspase-9, however this is likely a result of the SR-DEVD-FMK staining both active 
caspases 3 and 7. 
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Figure 3.28 Dot-plots of the caspase-9 flow cytometry experiments 
Representative dot-plots of the flow cytometry experiments with SR-LEHD-FMK to stain 
for caspase-9 activity.  Gated region is defined as positive for caspase-9 activity. 
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Figure 3.29 Statistical analysis of the caspase-9 flow cytometry experiments 
Analysis of Caspase-9 activation using SR-LEHD-FMK revealed that 24-hour treatment 
with 5 µM 10-Biphenoxy AIM causes an increase in Caspase-9 activation in SNB-19 
human glioblastoma cells (P = 0.002).  ANOVA P = 0.003.  Error bars represent 
standard deviation.  Dunnett post-hoc test used for comparisons between treatment and 
control groups.  Symbols represent significance levels (P < 0.05 *, P < 0.01 **, P < 
0.001 ***). 
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Figure 3.30 Dot-plots of the caspase-3/7 flow cytometry experiments 
Representative dot-plots of the flow cytometry experiments with SR-DEVD-FMK to stain 
for caspase-3/7 activity.  Gated region is defined as positive for caspase-3/7 activity.  
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Figure 3.31 Statistical analysis of the caspase-3/7 flow cytometry experiments 
Analysis of Caspase-3/7 activation using SR-LEHD-FMK showed that 24-hour treatment 
with 2.5 µM and 5 µM 10-Biphenoxy AIM causes an increase in Caspase-3/7 activation 
in SNB-19 human glioblastoma cells (2.5 µM treatment P = 0.05, 5 µM treatment P = 
0.002).  ANOVA P = 0.004.  Error bars represent standard deviation.  Dunnett post-hoc 
test used for comparisons between treatment and control groups.  Symbols represent 
significance levels (P < 0.05 *, P < 0.01 **, P < 0.001 ***) (n=3). 
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Discussion 
 In this work we elucidated a mitochondrial mechanism of action for the AIMs in 
tumor cells.  We also have provided evidence that suggests this mechanism contributes 
to their antitumor activity.  These data support the hypothesis that the AIMs can inhibit 
activity of ETC protein complexes and induce loss of the mitochondrial membrane 
potential (ΔΨm). 
Our confocal imaging experiments revealed that the auto-fluorescent AIMs 
display punctate binding in glioblastoma cells, indicating a distinct molecular target.  
Furthermore, the AIMs did not show a significant amount of fluorescence in the nucleus 
of SNB-19 cells (Appendix Figure A.3.2).  This should be an important consideration 
when considering the AIMs potential interactions with quadruplex DNA in the nucleus, 
as has been the focus of previous work by our laboratory and collaborators (Gajewski et 
al. 2009; Han et al. 2009; Mirzaei et al. 2012; Weaver et al. 2015).  However, this does 
not rule out the possibility of AIMs interaction with quadruplexes in nuclear DNA, as 
quenching of the AIMs fluorescence has been shown previously to occur when binding 
quadruplex structures (Han et al. 2009).  In contrast, the AIMs did appear to colocalize 
with the MitoTracker™ mitochondria specific fluorescent dye (Figure 3.6 and Figure 
3.7).  Inspection of the AIMs structure suggested it could accumulate in mitochondria, 
as this has been seen for other structures with similar lipophilic molecules containing 
tertiary amines (Smiley et al. 1991; Gorlach, Fichna, and Lewandowska 2015).  This led 
us to determine the cytotoxicity of the AIMs using an LDH cell viability assay not 
dependent on mitochondrial health for comparison to our previous MTT cell viability 
experiments that could be affected by mitochondria reductase activity. 
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The MTT cell viability results indicated the AIMs cause toxicity in tumor cells at 
low- to sub-micromolar concentrations in human glioblastoma cells (Figure 3.2 and 
Table 3.7). The LDH results overall showed less toxicity when compared to MTT results 
for the same cell lines and compounds (Table 3.7 and Table 3.8).  This can be 
interpreted in several ways, as the assays are different measures of cell viability.  It was 
postulated that one possible scenario would be the mitochondrial reductases 
responsible for reducing the MTT dye were being inhibited by the AIMs.  This could 
produce a lower measured IC50 in the MTT experiments relative to LDH; if the enzymes 
responsible for conversion of MTT to the measurable formazan were inhibited, it would 
appear less cells were viable in the assay.  However, one other possibility was a 
difference in toxicity due to the four-day incubation period that was utilized in the MTT 
experiments.  In the LDH experiments, the AIMs also displayed higher toxicity in the 
primary rat astrocytes compared to the rat glioma cell line (Table 3.8).  This is 
concerning, as the AIMs are being pursued as potential anticancer therapeutics.  
However, species differences (rat vs. human) and the specific mutations present in the 
C6 rat glioma cells may play a role in the toxicity of the AIMs.  Taken together, this 
suggests the AIMs should be tested in healthy human astrocytes and potentially other 
cancer lineages.  To determine if the AIMs were affecting mitochondrial reductase 
activity as suggested by comparison of the MTT and LDH data, we performed activity 
experiments in ETC complex proteins isolated from mitochondria and in whole intact 
mitochondria. 
The electron transport chain activity assays contributed several important 
findings regarding the activity of the AIMs on mitochondria.  Primarily, the studies 
 174 
demonstrate that the AIMs can act as low-micromolar inhibitors of ETC protein 
complexes in intact mitochondria, and more specifically in isolated Complex II (Table 
3.9).  This is a significant result as it demonstrates a plausible mitochondrial mechanism 
of action for the AIMs.  Complex II inhibition has been documented for other antitumor 
agents as their major mechanism of action (Chen et al. 2007; L.-F. Dong et al. 2008; 
Ralph et al. 2011).  In addition, the inhibition of Complex II was greater for the 10-
Biphenoxy AIM than the 10-Phenyl AIM, and this is consistent with their relative 
induction of apoptosis in SNB-19 cells as demonstrated in the LDH cell viability results.  
The Complex II + III assay also verifies inhibition in intact mitochondria, but as the assay 
cannot distinguish between Complex II or Complex III inhibition, it is possible the AIMs 
have activity at both.  However, it is noted that the inhibition in the intact mitochondria is 
less for both compounds and this would not be expected if a combined inhibitory effect 
was present.  It was also noted that the ratio of inhibition (10-Biphenoxy vs. 10-Phenyl) 
is also approximately two-fold greater in the Complex II only assay relative to the assay 
measuring combined Complex II + III activity. Together, these results could indicate that 
the activity at Complex II is the major inhibition target of the AIMs and this will be an 
important distinguishment in future studies.  To examine the potential mechanism of 
binding of the AIMs to Complex II, molecular docking studies were performed in 
collaboration with the Molecular Computational Core Facility (MCCF) at the University of 
Montana. 
Our molecular docking results suggest the AIMs are able to bind the ubiquinone 
sites of Complex II (Table 3.10 and Table 3.11).  These have been reported as binding 
sites for other Complex II inhibitors in the literature (Miyadera et al. 2003; Sun et al. 
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2005).  The poses generated by the GOLD docking algorithm also are chemically 
reasonable and the potential molecular interactions observed suggest the AIMs could fit 
and anchor themselves in the ubiquinone binding pockets (Figure 3.15 and Figure 
3.17). Although the molecular docking studies do not prove the mechanism of AIMs 
interaction with Complex II, the results could serve as an initial binding hypothesis for 
continued development of AIMs as ubiquinone-site inhibitors. Overall, the molecular 
docking studies were promising and were in support of our biochemical data. 
Our laboratory has previously observed an increase in mitochondrial ROS 
following AIMs treatment (Kearns 2013).  This is consistent with reports in the literature 
that inhibition of the mitochondrial ETC at various protein complexes can cause 
generation of ROS as superoxide and hydrogen peroxide (Sun et al. 2005; Chen et al. 
2007; L.-F. Dong et al. 2008; Bleier and Dröse 2013).  The production of ROS from 
mitochondrial ETC complexes has also been reported previously to cause damage to 
mtDNA  (Lan-Feng Dong et al. 2007).  With this in mind, we performed a time-course 
study using the AIM measured as the most potent complex II inhibitor to determine the 
effect of treatment on mtDNA. 
The 10-Biphenoxy AIM was also shown to reversibly induce mtDNA damage and 
reduce mtDNA copy number in glioblastoma cells (Figure 3.19, Figure 3.20, and 
Figure 3.21).  These findings were consistent with results previously observed where 
hydrogen peroxide treatment caused mtDNA damage and mtDNA copy number 
reduction, followed by recovery of mtDNA integrity at 24 hours in prostate cancer cells 
(Chan and Chen 2009).  Additionally, hydrogen peroxide treatment has also been 
shown to lead to loss of ΔΨm in cells (Li et al. 2003).  Taken together, our findings and 
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reports in the literature serve to reinforce our hypothesis that the increase in 
mitochondrial ROS following treatment with the AIMs is contributing to damage in 
mitochondria resulting in loss of ΔΨm. 
The loss of ΔΨm in glioblastoma cells following treatment with AIMs was 
demonstrated by our experiments using JC-1 with both a classical and alternative 
method of analysis.  The results suggest that low concentrations of AIMs treatment 
result in hyperpolarization of the mitochondria (Figure 3.25 and Figure 3.27).  This is 
consistent with our theory of Complex II mediated increase in oxidative stress causing 
hyperpolarization prior to permeabilization of the mitochondria membrane and the 
subsequent loss of ΔΨm.  Interestingly, it has also been previously observed that the 
hyperpolarization event occurs at the same time as the excessive ROS generation 
(Zorov, Juhaszova, and Sollott 2006).  Our results also showed a dose-dependent 
decrease in the number of cells with a normal ΔΨm with increasing doses of the 10-
Biphenoxy AIM.  These results suggested that the AIMs are disrupting ΔΨm; the loss of 
ΔΨm is also consistent with previous studies of ETC complex inhibitors effect on 
mitochondria leading to apoptosis in tumor cells (L.-F. Dong et al. 2008; Byun et al. 
2008; Ralph et al. 2011; Wang et al. 2016). 
 Our results also confirm activation of the mitochondrial-mediated intrinsic 
pathway of apoptosis, measured as an increase in caspase-9 activation (Figure 3.29).  
Furthermore, caspase-9 activity resulted in a measured increase in activity of 
executioner caspases 3/7 (Figure 3.31).  This confirms formation of the apoptosome by 
activated caspase-9, and initiation of intrinsic apoptosis.  Finally, induction of apoptosis 
in glioblastoma cells without a significant increase in necrosis was confirmed by 
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Annexin-V and propidium iodide staining (Figure 3.23).  Overall, our flow cytometry 
experiments demonstrate that the AIMs are inducing intrinsic apoptosis in glioblastoma 
cells leading to caspase activation and tumor cell death. 
 
Figure 3.32   
Our working hypothesis of the mechanism of intrinsic apoptosis induction by the AIMs 
through inhibition of ETC protein complexes in mitochondria. 
 
Collectively, these studies have provided strong evidence in support of a novel 
mitochondrial-associated mechanism of apoptosis, mediated through inhibition of ETC 
protein complexes, as a contributor to the antitumor activity of the AIMs (Figure 3.32).    
Future studies will investigate the mechanism of Complex II inhibition in depth with a 
focus on binding kinetics and measure the effect of AIMs on respiration and ATP 
production in mitochondria.  This work will act as the foundation for exploring the 
possibility of using AIMs designed to target Complex II as potential antitumor agents 
and guide the continued structure-based drug design of the AIMs. 
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Appendix 
10-Quinoline AIM 10-Phenyl AIM 10-Biphenoxy AIM 
   
Figure A.3.1   
SNB-19 cells treated with 1 µM of the 10-Quinoline AIM (left), 1 µM of the 10-Phenyl 
AIM (middle), and 1 µM of the 10-Biphenoxy AIM (right). 
 
10-Quinoline AIM HCS Nuclear Mask Overlay 
   
Figure A.3.2   
SNB-19 cells treated with 1 µM of the 10-Quinoline AIM (green, left), 1x HCS Nuclear 
Mask (magenta, middle), and overlay (white, right).  Scale bar shown is 20 µM. 
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Figure A.3.3   
Example of MDA-468 dose-response curve generated using the MTT cell viability assay 
as described (intermediate range).  Error bars represent standard deviations, IC50 
shown as a vertical black line with dotted lines representing the respective 95% 
confidence interval. 
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Figure A.3.4 
Example of C6 dose-response curve generated using the MTT cell viability assay as 
described (intermediate range).  Error bars represent standard deviations, IC50 shown 
as a vertical black line with dotted lines representing the respective 95% confidence 
interval. 
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Figure A.3.5 
Example of SNB-19 dose-response curve generated using the MTT cell viability assay 
as described (intermediate range).  Error bars represent standard deviations, IC50 
shown as a vertical black line with dotted lines representing the respective 95% 
confidence interval. 
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SNB-19 
(Human Glioblastoma) 
 
MDA-468 
(Human Breast Cancer) 
 
C6 
(Rat Glioma) 
MTT 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
Chloro 
 
2.41*‡ 0.55* 
      
Phenyl 
 
0.89*§ 0.02* 
 
0.82 0.03 
   
Biphenoxy 
 
0.68 0.04 
      
O-Pyridyl 
 
>25 
  
6.34† 0.67 
 
>25 
 
M-Pyridyl 
 
7.76 0.42 
 
1.29† 0.3 
 
>25 
 
P-Pyridyl 
 
7.08 0.26 
 
3.1† 0.27 
 
16.94 0.5 
Quinoline 
 
2.03 0.09 
 
1.17† 0.25 
 
6.71 0.12 
*Previously published in BMCL, error for these values is ±Standard Deviation 
§Matthew J. Weaver and ‡Alison K. Kearns performed these experiments. 
†Michael J. Campbell contributed to these experiments. 
 
Table A.3.1   
Summary of MTT Results for 10-substituted AIMs.  
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SNB-19 
(Human Glioblastoma) 
 
C6 
(Rat Glioma) 
 
E-18 
(Primary Rat Astrocytes) 
Compound 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
 
IC50 (µM) 95% CI (±) 
10-Phenyl AIM 
 
5.92 0.68 
 
3.76 0.12 
 
2.20 0.16 
10-Biphenoxy AIM 
 
4.44 0.16 
 
3.83 0.10 
 
2.09 0.20 
10-Quinoline AIM     17.46 0.58  18.32 0.76 
 
Table A.3.2 
Summary of LDH Results for 10-substituted AIMs.  
 189 
Complex I 
 
Figure A.3.6 
Complex I Inhibition by Rotenone 
Points represent individual measurements, curve represents three-parameter logistic fit 
with shaded area indicating the 95% confidence interval of the fit. (n=3) 
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Figure A.3.7  
Complex I Inhibition by 10-Phenyl AIM 
Points represent individual measurements. (n=3) 
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Figure A.3.8   
Complex I Inhibition by 10-Biphenoxy AIM 
Points represent individual measurements. (n=3) 
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Complex II + III 
 
Figure A.3.9 
Complex II + III inhibition curve for Antimycin A in intact mitochondria.  Points represent 
individual measurements, curve represents three-parameter logistic fit with shaded area 
indicating the 95% confidence interval of the fit. (n=3) 
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Complex IV 
 
Figure A.3.10   
Complex IV Inhibition by 10-Phenyl AIM 
Points represent individual measurements, curve represents three-parameter logistic fit 
with shaded area indicating the 95% confidence interval of the fit. (n=3) 
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Figure A.3.11  
Complex IV Inhibition by 10-Biphenoxy AIM 
Points represent individual measurements, curve represents three-parameter logistic fit 
with shaded area indicating the 95% confidence interval of the fit. (n=3) 
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Figure A.3.12 
Standards curves for D-loop mtDNA marker.  Analysis 1 contained two control samples, 
three 12-hour samples and three 24-hour samples (native & relaxed).  Analysis 2 
contained one control sample, three 3-hour samples, and three 6-hour samples (native 
& relaxed).  An exponential fit used to generate the standard curve.  
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Figure A.3.13 
Standards curves for CO-2 mtDNA marker.  Analysis 1 contained two control samples, 
three 12-hour samples and three 24-hour samples (native & relaxed).  Analysis 2 
contained one control sample, three 3-hour samples, and three 6-hour samples (native 
& relaxed).  An exponential fit used to generate the standard curve. 
 
  
Figure A.3.14 
Standards curves for Calicin nuclear DNA marker.  Analysis 1 contained two control 
samples, three 12-hour samples and three 24-hour samples (native & relaxed).  
Analysis 2 contained one control sample, three 3-hour samples, and three 6-hour 
samples (native & relaxed).  An exponential fit used to generate the standard curve. 
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mtDNA Damage and Copy Number (10-Phenyl AIM) 
  
Figure A.3.15 
Results for 1 µM treatment with 10-Phenyl AIM in D-loop gene of mtDNA (n=2) 
  
Figure A.3.16 
Results for 1 µM treatment with 10-Phenyl AIM in CO-2 gene of mtDNA (n=2) 
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Figure A.3.17 
Annexin-V/PI staining of 24-hour treatment with 10-Phenyl AIM at increasing 
concentrations in SNB-19 human glioblastoma cells.  Results of one experiment. 
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Figure A.3.18 
Annexin-V/PI staining of 24-hour treatment with 10-Quinoline AIM at increasing 
concentrations in SNB-19 human glioblastoma cells.  Results of one experiment. 
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Abstract 
 It has been demonstrated previously that certain forms of cancer overexpress an 
enzyme known as NAD(P)H:quinone oxidoreductase 1 (NQO1).  NQO1 can act to 
bioactivate antitumor agents through a reductive mechanism.  Previous reports have 
suggested structural analogs of the 5,8-quinolinedione moiety of the naturally occurring 
compound lavendamycin could serve as substrates for NQO1 and cause apoptosis in 
tumor cells through bioactivation and redox cycling.  In this work, we measure the 
activity of a novel set of 5,8-quinolinedione analogs in parent breast tumor cells and 
those overexpressing recombinant NQO1.  We also determine the suitability of this set 
of compounds as substrates for NQO1 using a spectrophotometric assay. 
 
Introduction 
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic, two-electron 
reductase that is characterized by its capacity for using either NADH or NADPH as 
reducing cofactors.  NQO1 has been categorized as a detoxification enzyme, and it can 
protect the cell from a broad range of chemically reactive metabolites (Riley and 
Workman 1992; Talalay and Dinkova-Kostova 2004).  However, NQO1 can also 
function as an activating enzyme and can reduce quinones and other bioreductive 
antitumor agents to form reactive metabolites that can damage DNA through alkylation, 
crosslinking, or generation of reactive oxygen species (Ross et al. 2000). 
In previous studies, the NQO1 activity in cancer cells has been positively 
correlated with the cytotoxicity of quinone antitumor agents  (H. D. Beall et al. 1995; 
Plumb, Gerritsen, and Workman 1994; Robertson et al. 1994).  Multiple series of indole- 
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and quinolinedione agents have been reported to be selectively toxic to cell lines with 
high NQO1 expression relative to those deficient in NQO1  (Howard D. Beall et al. 1998; 
Swann et al. 2001; Fryatt et al. 2004).  Increased NQO1 expression has also been 
observed in tumors or cell lines from lung, liver, colon, and breast cancer (Schlager and 
Powis 1990; Malkinson et al. 1992; Cresteil and Jaiswal 1991). 
Lavendamycin is a naturally occurring antibiotic that has been shown to have 
potent antitumor activity (Doyle et al. 1981) (Figure 4.1).  However, due to the non-
specific cytotoxicity observed with lavendamycin it is not used clinically (Fang et al. 
2003).  As a result of this, many synthetic analogs of lavendamycin have been 
developed to improve its solubility and therapeutic index (Hassani et al. 2005, 2008; Cai 
et al. 2010).  It has also been reported that synthetic analogs containing the 5,8-
quinolinedione moiety found in lavendamycin can overcome the associated non-specific 
cytotoxicity and be used as selective antitumor agents in cells overexpressing NQO1 
(Cai et al. 2010).  Together, these previous findings suggest there is potential for 
creating lavendamycin-inspired 5,8-quinolinedione analogs with improved efficacy and 
selectivity for treatment of cancers that overexpress NQO1. 
 
 
Figure 4.1 Structure of Lavendamycin 
(Keyari et al. 2013) 
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In this study we explored the cytotoxic effects of a set of novel 5,8-
quinolinediones (Figure 4.2; synthesis and characterization by Rob Sammelson’s 
laboratory at Ball State University, Muncie, IN) in two breast tumor cell lines with 
differing amounts of NQO1 expression to assess the relative cytotoxicity of these 
compounds by MTT assay. The MDA-468-WT breast tumor cell line was previously 
shown to have no measurable NQO1 activity.  In contrast, the MDA-468-NQ16 cell line, 
which has been stably transfected with NQO1, was shown to have approximately 1070 
nmol/min/mg (total cell protein) NQO1 activity as measured by reduction of 
dichlorophenolindophenol (DCPIP) (Keyari et al. 2013).  In addition, we performed a 
previously developed quinone reduction assay to determine the suitability of these 
compounds as substrates for NQO1-dependent reduction and subsequent re-oxidation, 
as measured by their ability to reduce cytochrome c (Keyari et al. 2013). 
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Figure 4.2 Novel 5,8-quinolinediones 
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Methods 
Cell Viability Assay 
MDA-468-WT or MDA-468-NQ16 cells were grown in RPMI-1640 medium with 
10% FBS, L-Glutamine (2 mM) and Penicillin-Streptomycin (1x, 100 µg/mL) added to 80 
- 90% confluence under optimal growth conditions (37 C, 5% CO2, humidified 
atmosphere).  Cells were washed with PBS (2 mL) and then treated with Trypsin EDTA 
(2 mL) to detach cells from culture flask prior to counting with a Coulter counter.  Cells 
were diluted to 10,000 cells / mL and plated on a 96-well plate with 100 µL per well 
(1000 cells / well).  Cells were grown in optimal growth conditions and allowed to adhere 
overnight. Treatment solutions were prepared in growth medium at various 
concentrations using a 5 mM compound stock solution prepared previously in sterile 
DMSO.  Medium was removed from the 96-well plate via aspiration and treatment 
solutions were added as outlined for the intermediate treatment range (Table 4.1). Cells 
were grown in treatment medium for 24 hours and then treatment medium was removed 
via aspiration and 100 µL of untreated growth medium was added to each well and cells 
were allowed to grow for a four-day growth period.  Following the growth period, 50 µL 
of MTT solution (1 mg/mL in growth medium) was added to each well and the 96-well 
plate was placed on a plate shaker for 5 minutes to mix.  The plate was then incubated 
at growth conditions for 4 hours before removing medium/MTT solution from the wells 
carefully via aspiration to avoid disturbing the formazan crystals.  One hundred µL of 
DMSO was then added to each well and the plate was placed on a plate shaker for 5 
minutes to dissolve the crystals.  A SpectraMax 190 plate reader was used to measure 
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the absorbance of the wells at 562 nm.  Three replicate experiments were run per 
compound. 
Table 4.1 96-well Plate Layout MTT Assay (Intermediate Range) 
Column: #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 
Treatment: 
No 
Cells 
Medium 
Control 
DMSO 
Control 
 
0.1 µM 
 
0.25 
µM 
0.5 µM 1 µM 2.5 µM 5 µM 10 µM 25 µM 
DMSO 
Control 
 
Data Analysis 
IC50 values were calculated using the ‘R’ statistical computing software and the ‘ic50’ 
package (R Core Team, 2014; Frommolt, 2010).  This package fits a logistic model to 
the dose-response data collected using the MTT assay and approximates the 
concentration of the compound required to inhibit the growth of the cells by 50% versus 
the DMSO control (IC50). 
 
Quinone Reduction Assay 
5,8-quinolinedione reduction was measured using a previously published method 
(Keyari et al. 2013).  The reaction mixture consisted of 70 µM cytochrome c combined 
with either 1 µg  (RRS-01 – RRS-08) or 0.25 µg (RRS-09 – RRS-12) of recombinant 
hNQO1 (gift from David Ross, University of Colorado Denver, Denver, CO) in a solution 
containing 25 µM of the test compound, 0.7 mg/mL of BSA, 0.1% Tween-20 and 25 mM 
Tris Buffer at pH 7.4.  Immediately prior to reading, 1 mM of NADH from a 20 mM stock 
was added to create a final volume of 1 mL in a cuvette with a 10 mm pathlength.  The 
solution was inverted to mix and change in absorbance at 550 nm was recorded 
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immediately using a SpectraMax M4 microplate reader in kinetic mode for 30 seconds.  
Each reaction was performed in triplicate.  Quinone reduction was defined as the rate of 
cytochrome c reduction in µmol/min/mg NQO1. 
Results 
Cell Viability 
 Cytotoxicity to the MDA-468 WT and NQ16 cells was determined using the MTT 
cell viability assay (Table 4.2).  All of the novel analogs were active against both cell 
lines at the single digit micromolar level, and several of the 5,8-quinolinedione showed 
submicromolar activity in the MDA-468 breast tumor cells.  The most active compound 
was the methyloxymethylisoxazole, RRS-10, with an IC50 value of 269 nM.  Three of the 
four N-hydroxyimino derivatives showed increased toxicity to the NQO1-transfected 
variant suggesting a role for this enzyme in selective toxicity.  RRS-02 had the highest 
WT/NQO1 IC50 ratio of 1.84, indicating a nearly two-fold greater toxicity to the NQO1-
expressing cells.  Cytotoxicity was greater going from R = methyl to R = isopropyl for 
the N-hydroxyimino compounds (RRS-01 – RRS-04), the reverse for t-butylisoxazoles 
(RRS-05 – RRS-08), and mixed for the methyoxymethylisoxazoles (RRS-09 – RRS-12). 
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Table 4.2 Cell viability results for RRS compounds 
Cell Viability Results 
Cell Line: MDA-468-WT MDA-468-NQ16 WT/NQ16 
Compound IC50 (µM) ± 95% CI IC50 (µM) ± 95% CI IC50 Ratio 
RRS-01 3.84 0.05 4.33 0.72 0.89 
 
RRS-02 2.99 0.18 1.62 0.10 1.84 
RRS-03 1.43 0.09 1.40 0.08 1.02 
RRS-04 1.35 0.12 0.81 0.04 1.67 
RRS-05 0.95 0.08 0.80 0.14 1.18 
RRS-06 1.13 0.07 1.66 0.07 0.68 
RRS-07 1.46 0.08 1.97 0.26 0.74 
RRS-08 3.16 0.13 3.68 0.05 0.86 
RRS-09 0.83 0.09 1.83 0.24 0.45 
RRS-10 0.27 0.02 0.45 0.02 0.60 
RRS-11 0.80 0.06 1.19 0.08 0.67 
RRS-12 0.73 0.03 0.63 0.04 1.17 
Table 4.2  
MTT Cell Viability Results for RRS compounds in MDA-468-WT and MDA-NQ16 breast 
cancer cells.  (n=3) 
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Quinone Reduction 
Quinone reduction was monitored using a spectrophotometric assay that 
measures cytochrome c reduction by the NQO1-reduced 5,8-quinolinedione (Table 
4.3). The methyloxymethylisoxazole compounds (RRS-09 – RRS-12) were by far the 
best NQO1 substrates, with reduction rates of approximately 100 µmol/min/mg NQO1.  
NQO1 reduction rates generally decreased with bulk at R as expected (exception was 
RRS-12).  Compound RRS-08 had the greatest bulk at both ends of the molecule and 
was by far the poorest substrate for NQO1. 
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Table 4.3 Quinone reduction results for RRS compounds 
Quinone Reduction Results 
Compound Red. Rate 
(µmol/min/mg) 
± SD 
RRS-01 25.75 1.72 
RRS-02 18.03 0.42 
RRS-03 20.13 0.07 
RRS-04 12.42 0.11 
RRS-05 19.18 0.79 
RRS-06 16.31 0.12 
RRS-07 13.30 0.22 
RRS-08 2.47* 0.09 
RRS-09 121.97 3.44 
RRS-10 90.90 8.00 
RRS-11 88.51 3.47 
RRS-12 107.41 3.02 
Quinone reduction results for RRS compounds using recombinant hNQO1.  (n=3, *n=2) 
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Discussion 
The novel 5,8-quinolinediones have excellent activity against both the NQO1-null 
and NQO1-expressing MDA-468-WT breast tumor cells, but exhibited mixed results 
regarding selectivity to NQO1-expressing cells.  The most NQO1 selective compounds 
were RRS-02 and RRS-04, and the most NQO1 protective were RRS-09 and RRS-10.  
However, many of the other analogs showed better activity in the parent cells, 
suggesting that NQO1 is protective against those compounds. This has been shown 
previously for simple 5,8-quinolinediones, whereas those compounds that more closely 
resemble the lavendamycin structure tend to be more selective to NQO1-expressing 
cells (Hassani et al. 2005, 2008; Behforouz et al. 2007; Keyari et al. 2013).  This result 
could also be due to involvement of other reductases in the breast cancer cells acting to 
convert the RRS compounds to bioactive metabolites, as has been suggested 
previously for other quinone-based compounds (Beall and Winski 2000).  This 
explanation would also align with the observation that although the 
methyloxymethylisoxazole compounds (RRS-09 – RRS-12) were the most suitable 
reduction substrates for NQO1 and had the highest antitumor activity, higher NQO1 
expression was also protective to the tumor cells for these compounds. 
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Conclusions 
 Cancer is a disease that will cause a hardship in the life of nearly every person in 
one way or another, whether it be a personal diagnosis of that of a family or friend.  The 
National Cancer Institute estimates nearly 40% of individuals in the United States will 
face a cancer diagnosis at some point during their lifetime (Siegel, Miller, and Jemal 
2018).  Through research, we have made great progress in treating some types of 
cancer; however, for other forms such as malignant cancers of the brain and central 
nervous system, the prognosis has remained quite grim (American Cancer Society 
2014).  The limited success in treatment of certain aggressive forms of cancer such as 
glioblastoma highlights the need to develop new strategies to create more effective 
therapies (Y. Wang et al. 2017).  This will almost certainly require the examination of 
new mechanistic targets to allow for creation of more selective and potent antitumor 
agents.  In this work, we detail our significant findings from studies of three distinct 
molecular targets as they relate to development of novel antitumor agents. 
 
Quadruplex DNA 
 Targeting quadruplex DNA for treatment of cancer has been the focus of an 
increasing number of research groups over the past two decades.  This has been 
catalyzed by the discovery of quadruplex-forming DNA sequences in human gene 
promoter regions and telomeres (Burge et al. 2006; Balasubramanian, Hurley, and 
Neidle 2011).  The realization that stabilizing quadruplex structures with small molecule 
ligands could affect gene expression and prevent telomere elongation suggests 
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development of these compounds could lead to creation of promising new anticancer 
drugs (Neidle 2017).  
 
Structure of the human c-MYC promoter quadruplex 
 We have reported and characterized the first high-resolution crystal structure of 
the major quadruplex formed in the human c-MYC promoter region (Stump et al. 2018).  
The oncogene c-MYC is overexpressed in approximately 70% of all human cancers, 
and reduction in c-MYC expression has been reported to induce apoptosis in multiple 
tumor cell types (Siddiqui-Jain et al. 2002; Ou et al. 2007).  Stabilization of the 
quadruplex formed in the c-MYC promoter with small molecules has been demonstrated 
to inhibit transcription and expression of c-MYC.  These previous findings illustrate the 
significance of the high-resolution crystal structure reported in this work.  The core 
region of the crystal structure is similar to that observed in NMR solution studies, 
however the flanking regions showed a previously uncharacterized conformation and 
presented a plausible alternative binding hypothesis (Stump et al. 2018).  This crystal 
structure will aid future and current endeavors to selectively target the c-MYC promoter 
quadruplex for development of anticancer therapies. 
 
AIMs interact with quadruplex DNA structures 
 In this work we provided evidence that the AIMs interact with quadruplex DNA 
structures.  Our circular dichroism spectroscopy thermal melting studies demonstrate 
the AIMs increase the stability of both 3+1 mixed and fully parallel quadruplex 
topologies formed by human telomeric and c-MYC promoter sequences (Weaver et al. 
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2015).  In contrast, we observed no significant stabilizing effect on an anti-parallel 
quadruplex formed in the COX I gene of mitochondrial DNA (Huang et al. 2015).  This 
suggests the AIMs chemical structure may discriminate between different quadruplex 
topologies as it relates to their binding.  Discovery of small molecules with selectivity 
between different quadruplex topologies and loop structures may be necessary to 
develop better therapeutics; our findings with the AIMs may present an opportunity to 
design these types of selective ligands (Burge et al. 2006; Neidle 2017).  The results 
with the CSB II DNA:RNA hybrid quadruplex demonstrate the remarkable stability of this 
structure and suggest it must be resolved by an enzyme such as a helicase in 
mitochondria to allow for transcription and replication of mitochondrial DNA.  Our NMR 
studies further confirm interaction of the AIMs with c-MYC promoter and telomeric 
quadruplex DNA sequences through anisotropy induced by the presence of the 
compounds in solution.  The solution NMR results also provide insight about the specific 
molecular interactions involved in stabilization of the c-MYC promoter and telomeric 
quadruplexes by the AIMs.  These studies together are informing development of the 
next generation of AIM compounds by the Natale laboratory for targeting quadruplex 
DNA (Weaver et al. 2015). 
 
Mitochondria 
AIMs localize to mitochondria and can inhibit mitochondrial ETC complexes 
Our confocal microscopy studies reveal that the AIMs localize to the 
mitochondria of glioblastoma cells as indicated by their punctate staining and 
colocalization with a mitochondria specific dye.  We have also shown that the AIMs 
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inhibit activity of the electron transport chain, specifically Complex II, and we provided 
insights into the potential mechanism of binding.  Further, we demonstrated several 
expected downstream effects of ETC protein complex inhibition.  Our results indicate 
treatment with the AIMs causes rapid damage to mtDNA and a loss in the intact mtDNA 
copy number in glioblastoma cells.  We also measured a loss of mitochondrial 
membrane potential resulting from treatment with the AIMs.  These results suggested 
that hyperpolarization of the mitochondria occurs at low AIM treatment concentrations, 
and the literature suggests that this event may precede loss of the mitochondrial 
membrane potential (Zorov, Juhaszova, and Sollott 2006).  Our molecular docking 
calculations also provide an initial binding hypothesis for AIMs interaction with the 
ubiquinone sites of Complex II.  Together, these studies will inform continued 
development of the AIMs and could provide the basis for designing AIMs to target the 
ubiquinone sites of Complex II for treatment of cancer. 
 
AIMs induce the intrinsic pathway of apoptosis in glioblastoma cells 
This work shows that treatment with the AIMs in glioblastoma cells causes 
activation of the mitochondrial-dependent intrinsic pathway of apoptosis.  This finding 
reinforces our hypothesis that destabilization in mitochondria following AIMs treatment 
is contributing to the induction of apoptosis.  In addition, it further demonstrates that the 
AIMs can overcome the resistance to apoptosis, a known “hallmark of cancer”, and 
cause tumor cell death.  This was verified through measurement of activated caspase-9, 
an initiator caspase, and the downstream executioner caspases 3 and 7.  Further, we 
show that the AIMs cause an increase in apoptosis without a corresponding increase in 
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necrosis.  This lack of necrosis is favorable for antitumor agents as the necrotic process 
often damages surrounding healthy tissue. 
 
NAD(P)H Quinone Oxidoreductase 1 (NQO1) 
Novel quinolinedione analogs reduce cell viability in breast cancer cells and the effect is 
not dependent on NQO1 expression or compound suitability as a substrate for NQO1 
Our studies in collaboration with the Sammelson laboratory at Ball State 
University showed that a novel series of quinolinedione analogs had sub-micromolar 
efficacy against breast cancer cells.  We evaluated the series of compounds in both a 
parent cell line and those transfected to overexpress NQO1.  Our results show that the 
cytotoxicity of the quinolinedione analogs did not depend on NQO1 expression as we 
initially expected.  However, our experiments did demonstrate the suitability of the 
compounds for reduction by NQO1.  Taken together, these results indicate that this 
series of quinolinedione analogs has significant antitumor activity that is not related to 
NQO1 expression.  This suggests that the activity of these compounds may be due to 
interactions with other reductases present in the cell and presents an opportunity for 
continued research.  
 
Future Directions 
The findings of this work contributed to the understanding of important targets for 
anticancer drug development, and the mechanism of action underlying the activity of 
two classes of novel antitumor compounds.  As a result, this has uncovered several new 
questions and opportunities for future research. 
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AIMs Interactions with Quadruplex DNA 
 These studies have provided the basis for developing a more complete 
understanding of the AIMs interaction with quadruplex DNA.  Our crystallization 
experiments and the knowledge gained regarding the c-MYC promoter quadruplex have 
already begun to be applied to co-crystallization studies with the AIMs, and success in 
this endeavor will greatly benefit the continued development of these compounds. 
The CD spectroscopy experiments demonstrate the feasibility of utilizing this method for 
the AIMs and could be expanded to other quadruplex-forming DNA sequences to 
develop a better understanding of the AIMs measured preference for certain quadruplex 
topologies. 
 
AIMs Activity at the Electron Transport Chain 
Our work has shown the capability of the AIMs to inhibit the electron transport 
chain, specifically Complex II, and proposed an initial binding hypothesis for 
consideration.  However, studies to measure the impact of the AIMs on mitochondrial 
function in the presence of other ETC inhibitors could provide additional insights 
regarding their specificity for Complex II and the mechanism of inhibition.  Our cell 
viability studies with primary rat astrocytes highlight the importance of measuring the 
toxicity of these compounds against healthy human cells in the future.  It would also be 
prudent to screen the AIMs against additional tumor cell lines arising from types of 
cancer that have been shown to be sensitive to Complex II inhibition such as breast and 
skin cancer (L. Wang et al. 2016; Guo et al. 2016). 
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Summary 
 Collectively, this work has revealed several significant findings that will be 
important to future endeavors in antitumor drug development.  The characterization of 
the c-MYC promoter quadruplex we report is the first definitive high-resolution crystal 
structure of this important anticancer target and will provide the basis for design of 
targeted quadruplex-ligands.  Our mechanistic studies with the AIMs demonstrate a 
plausible mitochondrial mechanism of action through inhibition of the electron transport 
chain protein complexes, specifically Complex II, and disruption of the mitochondrial 
membrane potential.  This is a novel mechanism that has not been previously shown for 
these compounds and demonstrates their potential for development as mitochondrial 
medicines for treatment of cancer.  Taken together, the studies presented here advance 
the field of anticancer therapeutics through elucidation of the molecular structure of an 
important target, the c-MYC promoter quadruplex, and by laying the foundation for 
continued development of the AIMs as antitumor agents. 
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